US20210093528A1 - Oral Care Compositions With Anticaries Activity - Google Patents

Oral Care Compositions With Anticaries Activity Download PDF

Info

Publication number
US20210093528A1
US20210093528A1 US17/037,780 US202017037780A US2021093528A1 US 20210093528 A1 US20210093528 A1 US 20210093528A1 US 202017037780 A US202017037780 A US 202017037780A US 2021093528 A1 US2021093528 A1 US 2021093528A1
Authority
US
United States
Prior art keywords
oral care
fluoride
care composition
composition
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/037,780
Other languages
English (en)
Inventor
Samuel James St. John
Arif Ali Baig
Aaron Reed Biesbrock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Priority to US17/037,780 priority Critical patent/US20210093528A1/en
Assigned to THE PROCTER & GAMBLE COMPANY reassignment THE PROCTER & GAMBLE COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAIG, ARIF ALI, BIESBROCK, AARON REED, ST. JOHN, SAMUEL JAMES
Publication of US20210093528A1 publication Critical patent/US20210093528A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A61K8/21—Fluorides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/48—Thickener, Thickening system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention is directed to compositions with anticaries activity.
  • the present invention is also directed to compositions with two or more anticaries agents that are individually subtherapeutic, but that have an overall therapeutic anticaries activity.
  • the present invention is also directed to fluoride-free compositions with an equivalent or greater anticaries benefit than a composition comprising a therapeutic amount of fluoride ions.
  • the present invention is also directed to compositions comprising a therapeutic amount of fluoride and another anticaries agent with a greater anticaries benefit than a composition comprising a therapeutic amount of fluoride ions as the sole anticaries agent.
  • the current consumer goods marketplace reflects an increasing awareness of the entire lifecycle of a product, including the provenance of the various ingredients, packaging, and research methods used to substantiate a product's effectiveness. Consumers are rejecting petrochemically derived ingredients and shifting the marketplace to responsible-sourced and naturally-derived raw materials, recyclable packaging, and minimally processed materials. Coupled with this trend is a rejection of fluoride for concerns, real or imagined, of its toxicity in drinking water, toothpaste, or both. This trend has provably led to increases in cavities in consumers whom reject fluoride because there are no viable alternatives to fluoride in over-the-counter oral care products for the prevention of cavities. Consequently, the current marketplace requires that consumers trade clean (giving up fluoride) for effective (anticavity toothpaste).
  • anticavity, fluoride-free oral care composition wherein the composition has a rat caries score of about 60% or more of a rat caries score of a positive control oral care composition, the positive oral care composition comprising 1100 ppm of sodium fluoride.
  • an oral care composition comprising (a) a first subtherapeutic anticaries agent (b) a second subtherapeutic anticaries agent, wherein the oral care composition is free of a fluoride source and the first and second subtherapeutic anticavity agents collectively have a therapeutic anticavity benefit.
  • an oral care composition comprising (a) an anticaries drug composition comprising fluoride; and (b) a subtherapeutic anticaries agent, wherein the subtherapeutic anticaries agent is free of fluoride, wherein the oral care composition has a therapeutic benefit greater than the anticaries drug composition.
  • FIG. 1 shows rat caries results for the invention relative to the fluoride control products.
  • FIG. 2 shows iPGRM dose response of chlorhexidine (% acid reduction v Crest Cavity Protection) along with the iPGRM performance of the novel compositions
  • FIG. 3 shows iPUM behavior of different calcium sources (ratio of biofilm calcium content following treatment relative to the biofilm calcium content following treatment with Crest Cavity Protection) along with the iPUM performance of the novel compositions
  • FIG. 4 shows F-Free HAP solubility reduction with respect to Sn content along with the F-Free HAP Solubility reduction of typical Sn/silica toothpaste compositions.
  • FIG. 5 shows actual v predicted rat caries percent reduction vs. placebo (left) and the plot of residuals (right).
  • Caries is a process by which tooth damage occurs by exposure to plaque acids and the subsequent net demineralization of the tooth.
  • Bacteria in the plaque produce organic acids from the metabolism of fermentable carbohydrates to which they have access when a person eats. Consequently, avenues for intervention in caries generally involve the suppression of acid formation and/or the stabilization of the tooth surface.
  • we have considered four mechanisms through which this may occur namely: i) suppressing acid formation via antibacterial action; ii) reducing enamel solubility through a calcium co-ion effect; iii) reducing enamel solubility through a fluoride co-ion effect; and iv) reducing enamel solubility through surface adsorbed stabilizers. These mechanisms are considered essential for the reduction in human cavities. Until now, the one favored by nearly every anti-cavity product on the market is exclusively the reduction of enamel solubility through a fluoride co-ion effect.
  • the present invention is directed at compositions that can treat caries and prevent cavities comprising two or more subtherapeutic anticaries agents, such as an antibacterial agent, a surface-adsorbed enamel stabilizing agent, a calcium ion source, and/or a fluoride ion source. Additionally, the present invention is directed at compositions with improved anticaries activity comprising a therapeutic amount of fluoride ions and one or more subtherapeutic anticaries agents, such as an antibacterial agent, a surface-adsorbed enamel stabilizing agent, or calcium ion source.
  • subtherapeutic anticaries agents such as an antibacterial agent, a surface-adsorbed enamel stabilizing agent, or calcium ion source.
  • the present invention is directed to creating a therapeutic oral care composition that is a combination of two or more sub-therapeutic compositions using a model for the performance of oral care compositions generally in rat caries along the vectors of fluoride co-ion effect, calcium co-ion effect, Sn-free antibacterial efficacy, and F-Free hydroxyapatite solubility reduction via surface adsorption.
  • a model for the performance of oral care compositions generally in rat caries along the vectors of fluoride co-ion effect, calcium co-ion effect, Sn-free antibacterial efficacy, and F-Free hydroxyapatite solubility reduction via surface adsorption.
  • Such a model will allow the rapid, ethical, and responsible identification of ingredients that minimizes or virtually eliminates animal testing for new therapeutic anti-caries oral care compositions to create fluoride-free and enhanced-fluoride compositions.
  • the present invention is directed to compositions comprising at least two subtherapeutic compositions in accord with the mechanisms described above, yet the disclosed compositions delivered a reduction in caries as measured in the rat caries model at least equivalent to 1100 ppm F as sodium fluoride and superior to that of the 1100 ppm F control when fluoride was included, as shown in FIG. 1 . Additionally, the disclosed compositions led to a reduction of caries in the rat sulcus and interproximal spaces that exceeded the effectiveness of fluoride. This unexpected result demonstrated that this approach was novel as nowhere in the art was it taught that a combination of subtherapeutic compositions could be effective for the prevention of cavities.
  • the rat caries results, presented in FIG. 1 indicated that Ex 1b reduced caries relative to sodium fluoride/silica and monofluorophosphate/silica compositions in a placebo-controlled study.
  • Ex. 1b which did not have fluoride, had a total caries reduction equivalent to the sodium fluoride/silica control product; however, it had an unexpectedly large reduction in sulcal caries relative to control.
  • the disclosed compositions were designed to work on the tooth and in the biofilm with a collection of subtherapeutic compositions. This has led to a remarkable reduction in sulcal and interproximal caries with respect to the control compositions.
  • fluoride is added to the disclosed compositions, as in Ex. 1d, the reduction in caries is enhanced with a notable reduction in smooth surface caries.
  • a composition's antibacterial efficacy should be determined with respect to its Sn placebo or by other experimental design approaches that correctly account single variably for the contribution of Sn in the iPGRM.
  • a composition's ability to reduce hydroxyapatite solubility should be determined using the fluoride-free version of the composition (if it contains fluoride) or by some other experimental design that correctly controls for fluoride's contribution.
  • TABLE 3 shows the variation in anticaries efficacy with respect to soluble fluoride content as determined by the ADA method.
  • a 650 ppm fluoride as sodium fluoride was estimated to effect a reduction in caries of about 29%, or about 25%, or about 30%, with respect to the placebo or water control in rat caries experiments.
  • TABLE 4 shows the variation in anticaries efficacy with respect to Sn-Free antibacterial activity as measured by the Sn-Free iPGRM using the dose responsive reduction in rat caries from a well-known antibacterial, chlorhexidine. These compositions were then analyzed using iPGRM to define the variation in rat caries effectiveness relative to its antibacterial efficacy. Since the iPGRM measures reduction in antibacterial efficacy through changes in the pH, non-antibacterial agents that buffer pH, such as sodium bicarbonate, can be corrected for when determining the efficacy of the antibacterial agent. This can be done using placebo controls as appropriate to isolate the Sn-Free antibacterial contribution. The contribution of Sn was measured through the solubility reduction and is excluded from this test. The iPGRM dose response of chlorhexidine is shown in FIG. 2 .
  • TABLE 5 shows the variation in anticaries efficacy with respect to calcium co-ion effect as measured by the iPUM.
  • This method measures the total calcium uptake of both soluble and insoluble sources. If an insoluble source was used, calcium sources were preferred that were substantially more soluble than hydroxyapatite so that they will dissolve preferentially when exposed to plaque acids. For example, dicalcium phosphate dihydrate or calcium carbonate dissolve readily on exposure to acid while calcium pyrophosphate is a poor source of calcium for the purposes here. Insoluble sources have the advantage of increased residence time in the plaque and can, therefore, provide a bloom of calcium to correspond temporally to the generation of plaque acid.
  • the iPUM dose response of calcium-containing compositions is shown in FIG. 3 .
  • TABLE 6 shows the variation in anticaries efficacy with respect to the F-Free reduction in HAP solubility as measured by F-free HAP.
  • the contribution of the fluoride co-ion effect is measured through the ADA method and is excluded from this test.
  • An example of the F-free HAP response for different levels of Sn in Sn/silica toothpastes is given in FIG. 4 .
  • the threshold can be defined for which combinations of subtherapeutic compositions result in a therapeutic composition.
  • therapeutic compositions can be defined as those providing a reduction in caries at least about equivalent to that of a 650 ppm available F as NaF/silica toothpaste and/or at least about 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, or 34% reduction in caries.
  • Caries reduction and/or anticavity activity can be substantiated using an actual rat caries performance test.
  • This threshold can be a guide during development of new compositions for when reductions achieve an approximately similar therapeutic level of benefit to that of a 650 ppm available F as NaF/silica toothpaste with respect to the placebo or water control.
  • Rat caries is the preferred animal model for human caries and is included in the US Anticaries Monograph (21 CFR part 355) to ensure the efficacy of fluoride-containing products. It is additionally sensitive to non-fluoride anticaries mechanisms and compositions.
  • animal models for caries are generally considered interchangeable as long as they have been properly developed.
  • the present invention is directed to a combination of subtherapeutic compositions that can result in a therapeutic composition when tested in total.
  • the examples can allow for the setting of performance thresholds for the subtherapeutic to therapeutic transition in each mechanism as defined by the specified performance test. However, those results, alone, might not anticipate the combined performance of the compositions in a rat caries experiment.
  • the analysis gave a model from which can predict reductions in rat caries for combinations of subtherapeutic compositions as described herein.
  • the examples, performance thresholds, and mathematical model can help define the present invention.
  • soluble fluoride sources are frequently deactivated by calcium unless special care is taken.
  • Cationic antibacterial agents can be deactivated by anionic surfactants.
  • stannous ion sources can necessitate the careful choice of stabilizers and packaging to prevent loss and/or oxidation.
  • Calcium pyrophosphate does not readily dissolve on exposure to plaque acid and is a poor source of calcium for the purposes of protecting teeth from plaque acids through a co-ion effect. There are many more examples like this that require expertise in the art to overcome.
  • oral care composition includes a product, which in the ordinary course of usage, is not intentionally swallowed for purposes of systemic administration of particular therapeutic agents, but is rather retained in the oral cavity for a time sufficient to contact dental surfaces or oral tissues.
  • oral care compositions include dentifrice, tooth gel, subgingival gel, mouth rinse, mousse, foam, mouth spray, lozenge, chewable tablet, chewing gum, tooth whitening strips, floss and floss coatings, breath freshening dissolvable strips, or denture care or adhesive product.
  • the oral care composition may also be incorporated onto strips or films for direct application or attachment to oral surfaces.
  • dentifrice composition includes tooth or subgingival -paste, gel, or liquid formulations unless otherwise specified.
  • the dentifrice composition may be a single-phase composition or may be a combination of two or more separate dentifrice compositions.
  • the dentifrice composition may be in any desired form, such as deep striped, surface striped, multilayered, having a gel surrounding a paste, or any combination thereof.
  • Each dentifrice composition in a dentifrice comprising two or more separate dentifrice compositions may be contained in a physically separated compartment of a dispenser and dispensed side-by-side.
  • Active and other ingredients useful herein may be categorized or described herein by their cosmetic and/or therapeutic benefit or their postulated mode of action or function. However, it is to be understood that the active and other ingredients useful herein can, in some instances, provide more than one cosmetic and/or therapeutic benefit or function or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated function(s) or activities listed.
  • orally acceptable carrier comprises one or more compatible solid or liquid excipients or diluents which are suitable for topical oral administration.
  • compatible is meant that the components of the composition are capable of being commingled without interaction in a manner which would substantially reduce the composition's stability and/or efficacy.
  • the carriers or excipients of the present invention can include the usual and conventional components of mouthwashes or mouth rinses, as more fully described hereinafter: Mouthwash or mouth rinse carrier materials typically include, but are not limited to one or more of water, alcohol, humectants, surfactants, and acceptance improving agents, such as flavoring, sweetening, coloring and/or cooling agents.
  • substantially free refers to the presence of no more than 0.05%, preferably no more than 0.01%, and more preferably no more than 0.001%, of an indicated material in a composition, by total weight of such composition.
  • essentially free means that the indicated material is not deliberately added to the composition, or preferably not present at analytically detectable levels. It is meant to include compositions whereby the indicated material is present only as an impurity of one of the other materials deliberately added.
  • therapeutic anticaries activity is the anticaries activity provided by a composition including an anticaries drug and/or one or more anticaries agents in a therapeutic dose.
  • a therapeutic dose for fluoride ions is defined in the United States by the Food and Drug Administration (FDA) Monograph (21 CFR part 355).
  • FDA Food and Drug Administration
  • a therapeutic amount of sodium fluoride in a paste dosage form i.e. paste dentifrice
  • Other anticaries drugs are disclosed in 21 CFR part 355, which is herein incorporated by reference.
  • Other therapeutic dosages are available in respective jurisdictions.
  • therapeutic anticaries activity for a composition comprising one or more anticaries agents is the anticaries benefit which is equivalent or better than the anticaries benefit provided by a composition comprising sodium fluoride with at least 650 ppm of available fluoride ions.
  • subtherapeutic anticaries activity is the anticaries activity of a composition that has a lower anticaries benefit relative to the anticaries benefit provided by a composition comprising sodium fluoride with at least 650 ppm of available fluoride ions, as defined in “therapeutic anticaries drug composition.”
  • the term “subtherapeutic anticaries activity” also can also describe anticaries agents that can, in combination with additional anticaries agents, lead to a therapeutic benefit relative to the anticaries benefit provided by a composition comprising sodium fluoride with at least 650 ppm of available fluoride ions, when utilized in an oral care composition suitable for use in the oral cavity of a human, but alone has not been shown to provide a therapeutic benefit at concentrations suitable for use in an oral care composition.
  • antiicaries drug is a drug that aids in the prevention and prophylactic treatment of dental cavities (decay, caries). This can include fluoride ion sources, such as in 21 CFR part 355 and anticaries agents, as described herein.
  • compositions and methods are described herein in terms of “comprising” various components or steps, the compositions and methods can also “consist essentially of” or “consist of” the various components or steps, unless stated otherwise.
  • the word “or” when used as a connector of two or more elements is meant to include the elements individually and in combination; for example, X or Y, means X or Y or both.
  • groups of elements are indicated using the numbering scheme indicated in the version of the periodic table of elements published in Chemical and Engineering News, 63(5), 27, 1985.
  • a group of elements can be indicated using a common name assigned to the group; for example, alkali metals for Group 1 elements, alkaline earth metals for Group 2 elements, and so forth.
  • the term “about” means that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but can be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement errors, and the like, and other factors known to those of skill in the art. In general, an amount, size, formulation, parameter or other quantity or characteristic is “about” or “approximate” whether or not expressly stated to be such. The term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term “about,” the claims include equivalents to the quantities. The term “about” can mean within 10% of the reported numerical value, preferably within 5% of the reported numerical value.
  • the dentifrice composition can be in any suitable form, such as a solid, liquid, powder, paste, or combinations thereof.
  • the oral care composition can be dentifrice, tooth gel, subgingival gel, mouth rinse, mousse, foam, mouth spray, lozenge, chewable tablet, chewing gum, tooth whitening strips, floss and floss coatings, breath freshening dissolvable strips, or denture care or adhesive product.
  • the components of the dentifrice composition can be incorporated into a film, a strip, a foam, or a fiber-based dentifrice composition.
  • Section headers are provided below for organization and convenience only. The section headers do not suggest that a compound cannot be within more than one section. In fact, compounds can fall within more than one section.
  • stannous chloride can be both a tin ion source and a surface adsorbed stabilizer
  • stannous fluoride can be both a tin ion source and a fluoride ion source
  • glycine can be an amino acid, a buffering agent, and/or a surface adsorbed stabilizer, among numerous other compounds that can fit amongst several categories and/or sections.
  • the oral care compositions can comprise one or more anticaries agents, which collectively demonstrate therapeutic anticaries activity.
  • therapeutic anticaries activity is defined by the relevant regulatory agency in a jurisdiction of interest, such as the U.S. FDA in the United States.
  • a therapeutic amount of sodium fluoride in a paste dosage form i.e. paste dentifrice
  • a therapeutic amount of sodium fluoride in a paste dosage form is 850 to 1,150 ppm with an available fluoride ion concentration of at least 650 ppm.
  • the oral care compositions of the present invention can have an anticaries benefit at least about of the anticaries benefit of a composition comprising at least, at least about, or greater than 650 ppm, 800 ppm, 850 ppm, 1100 ppm, 1150 ppm, 1450 ppm, and/or 2800 ppm of free fluoride ions, which can correspond to therapeutic anticaries activity.
  • the anticaries activity of the oral care compositions can also be described by a rat caries score.
  • the oral care compositions can have a rat caries score of about 35 or less, about 30 or less, about 25 or less, and/or about 20 or less.
  • the anticaries activity of the oral care compositions, as described herein can also be described the percent reduction of the rat caries score relative to a placebo toothpaste.
  • the oral care compositions can have a percent reduction in caries relative to a placebo toothpaste (i.e. a negative control) of at least about 25%, at least about 29%, at least about 30%, at least about 35%, and/or at least about 40%.
  • the anticaries activity of the oral care compositions can also be described by a percent reduction of the rat caries score relative to an oral care composition comprising a therapeutic dose of an anticaries agent (i.e. a positive control, such as USP NaF).
  • a positive control such as USP NaF
  • the oral care compositions can have a percent reduction in caries relative to a positive control, such as USP NaF, of about 50% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 90% or more, about 100% or more, about 125% or more, and/or about 150% or more.
  • the oral care composition as described herein, comprise one or more anticaries compositions, the one or more anticaries compositions comprising one or more anticaries agents, which can, individually, be in a therapeutic dose or a subtherapeutic dose.
  • the oral care composition can comprise a first subtherapeutic anticaries agent and a second subtherapeutic anticaries agent, which in total lead to a therapeutic anticaries benefit.
  • the first and second subtherapeutic anti caries agents can be fluoride-free, as described herein, or one of the subtherapeutic agents can comprise a subtherapeutic amount of fluoride ions.
  • the oral care composition can comprise a therapeutic anticaries agent comprising a fluoride ion source and a subtherapeutic anticaries agent, which is free from a fluoride ion source, where the overall oral care composition has a higher anticaries benefit than the anticaries benefit associated with the a therapeutic anticaries composition alone.
  • the anticaries activity of a composition comprising a therapeutic anticaries agent and a subtherapeutic anticaries agent can allow for anticaries activity that is normally available with a prescription strength concentration of fluoride ions.
  • the anticaries agent can be active against caries through one of these four mechanisms: i) suppressing acid formation via antibacterial action; ii) reducing enamel solubility through a calcium co-ion effect; iii) reducing enamel solubility through a fluoride co-ion effect; and iv) reducing enamel solubility through surface adsorbed stabilizers.
  • the anticaries agent can be an antibacterial agent, a calcium ion source, a fluoride ion source, a surface adsorbed stabilizer.
  • a compound can fall within more than one of these categories, such as, for example, stannous chloride, which can be an antibacterial agent and a surface adsorbed stabilizer or stannous fluoride, which can be an antibacterial agent, a fluoride ion source, and a surface adsorbed stabilizer.
  • stannous chloride which can be an antibacterial agent and a surface adsorbed stabilizer
  • stannous fluoride which can be an antibacterial agent, a fluoride ion source, and a surface adsorbed stabilizer.
  • the oral care composition can comprise one or more anticaries agents, the one or more anticaries agents can comprise one or more antibacterial agents.
  • the antibacterial agent can be any agent that suppresses acid formation by the bacteria of dental caries. Suitable antibacterial agents include agents that those that can provide at least about an 80%, or about 30%, 60%, 65%, 75%, 85%, 90%, or 95%, reduction in ⁇ pH with respect to Crest® Cavity Protection that thereby reduce caries at least about 9%, or about 1%, 6%, 7%, 8%, 10%, 11%, or 12%, with respect to the placebo or water control in rat caries experiments.
  • Suitable antibacterial agents include hops acids, such as hops alpha acids, hops beta acids, hydrogenated hops acids, and/or combinations thereof.
  • Other suitable antibacterial agents include metal ion sources, such as tin ion sources, zinc ion sources, copper ion sources, and/or combinations thereof.
  • Other suitable antibacterial agents include triclosan, extracts from any species within the genus Magnolia, extracts from any species within the genus Humulus.
  • Suitable antibacterial agents include hops acids, tin ion sources, benzyl alcohol, sodium benzoate, menthylglycyl acetate, menthyl lactate, L-menthol, o-neomenthol, chlorophyllin copper complex, phenol, oxyquinoline, and/or combinations thereof.
  • Other suitable antibacterial agents include one or more amino acids, such as basic amino acids.
  • the oral care composition can comprise from about 0.01% to about 10%, from about 1% to about 5%, or from about 0.5% to about 15% of an antibacterial agent. Some, but not all, suitable antibacterial agents will be discussed separately.
  • the oral care composition can comprise one or more anticaries agents, the one or more anticaries agents can comprise one or more surface adsorbed stabilizers.
  • the surface adsorbed stabilizer can be any agent that can adsorb on an enamel surface.
  • a suitable surface adsorbed stabilizer can be any compound that can provide at least a 17%, at least a 5%, or at least a 20%, at least a 30%, and/or at least a 15%, reduction in solubility relative to water in the F-free HAP dissolution method, which thereby reduces caries at least 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, and/or 18% with respect to the placebo or water control in rat caries experiments.
  • Suitable surface adsorbed stabilizers include metal ion sources, such as tin ion sources, zinc ion sources, copper ion sources, aluminum ion sources, titanium ion sources and/or combinations thereof.
  • Other suitable surface adsorbed stabilizers include bioactive materials, amino acids, and/or combinations thereof. Some, but not all, suitable surface adsorbed stabilizes will be discussed separately.
  • the oral care compositions of the present invention can comprise at least one hops compound from Formula I and/or Formula IV.
  • the compound from Formula I and/or Formula IV can be provided by any suitable source, such as an extract from Humulus lupulus or Hops, Humulus lupulus itself, a synthetically derived compound, and/or salts, prodrugs, or other analogs thereof.
  • the hops extract can comprise one or more hops alpha acids, one or more hops iso-alpha acids, one or more hops beta acids, one or more hops oils, one or more flavonoids, one or more solvents, and/or water.
  • Suitable hops alpha acids can include humulone (Formula II), adhumulone, cohumulone, posthumulone, prehumulone, and/or mixtures thereof.
  • Suitable hops iso-alpha acids can include cis-isohumulone and/or trans-isohumulone.
  • the isomerization of humulone into cis-isohumulone and trans-isohumulone can be represented by Formula III.
  • A is the acidic hydroxyl functional group in the alpha position
  • B are the acidic hydroxyl functional groups in the beta position
  • R is an alkyl functional group
  • Suitable hops beta acids can include lupulone, adlupulone, colupulone, and/or mixtures thereof.
  • a suitable hops beta acid can include a compound a described in Formula IV, V, VI, and/or VII.
  • B are the acidic hydroxyl functional groups in the beta position and R is an alkyl functional group.
  • hops alpha acids can demonstrate some antibacterial activity
  • hops alpha acids also have a bitter taste.
  • the bitterness provided by hops alpha acids can be suitable for beer, but are not suitable for use in oral care compositions.
  • hops beta acids can be associated with a higher antibacterial and/or anticaries activity, but not as bitter a taste.
  • a hops extract with a higher proportion of beta acids to alpha acids than normally found in nature can be suitable for use in oral care compositions for use as an antibacterial and/or anticaries agent.
  • a natural hops source can comprise from about 2% to about 12%, by weight of the hops source, of hops beta acids depending on the variety of hops.
  • Hops extracts used in other contexts, such as in the brewing of beer can comprise from about 15% to about 35%, by weight of the extract, of hops beta acids.
  • the hops extract desired herein can comprise at least about 35%, at least about 40%, at least about 45%, from about 35% to about 95%, from about 40% to about 90%, or from about 45% to about 99%, of hops beta acids.
  • the hops beta acids can be in an acidic form (i.e. with attached hydrogen atom(s) to the hydroxl functional group(s)) or as a salt form.
  • a suitable hops extract is described in detail in U.S. Pat. No. 7,910,140, which is herein incorporated by reference in its entirety.
  • the hops beta acids desired can be non-hydrogenated, partially hydrogenated by a non-naturally occurring chemical reaction, or hydrogenated by a non-naturally occurring chemical reaction.
  • the hops beta acid can be essentially free of or substantially free of hydrogenated hops beta acid and/or hops acid.
  • a non-naturally occurring chemical reaction is a chemical reaction that was conducted with the aid of chemical compound not found within Humulus lupulus, such as a chemical hydrogenation reaction conducted with high heat not normally experienced by Humulus lupulus in the wild and/or a metal catalyst.
  • a natural hops source can comprise from about 2% to about 12%, by weight of the hops source, of hops alpha acids.
  • Hops extracts used in other contexts, such as in the brewing of beer can comprise from about 15% to about 35%, by weight of the extract, of hops alpha acids.
  • the hops extract desired herein can comprise less than about 10%, less than about 5%, less than about 1%, or less than about 0.5%, by weight of the extract, of hops alpha acids.
  • Hops oils can include terpene hydrocarbons, such as myrcene, humulene, caryophyllene, and/or mixtures thereof.
  • the hops extract desired herein can comprise less than 5%, less than 2.5%, or less than 2%, by weight of the extract, of one or more hops oils.
  • Flavonoids present in the hops extract can include xanthohumol, 8-prenylnaringenin, isoxanthohumol, and/or mixtures thereof.
  • the hops extract can be substantially free of, essentially free of, free of, or have less than 250 ppm, less than 150 ppm, and/or less than 100 ppm of one or more flavonoids.
  • hops acids have been previously added to oral care compositions.
  • the oral care compositions taught by U.S. Pat. No. 5,370,863 only included up to 0.01%, by weight of the oral care composition. While not wishing to be bound by theory, it is believed that U.S. Pat. No. 5,370,863 could only incorporate a low amount of hops acids because of the bitterness of hops alpha acids. A hops extract with a low level of hops alpha acids would not have this concern.
  • the hops compound can be combined with or free from an extract from another plant, such as a species from genus Magnolia.
  • the hops compounds can be combined with or free from triclosan.
  • the oral care composition can comprise from about 0.01% to about 10%, greater than 0.01% to about 10%, from about 0.05%, to about 10%, from about 0.1% to about 10%, from about 0.2% to about 10%, from about 0.2% to about 10%, from about 0.2% to about 5%, from about 0.25% to about 2%, from about 0.05% to about 2%, or from greater than 0.25% to about 2%, of hops beta acid, as described herein.
  • the hops beta acids can be provided by a suitable hops extract, the hops plant itself, or a synthetically derived compound.
  • the hops beta acid can be provided as neutral, acidic compounds, and/or as salts with a suitable counter ion, such as sodium, potassium, ammonia, or any other suitable counter ion.
  • the hops beta acid can be provided by a hops extract, such as an extract from Humulus lupulus with at least 35%, by weight of the extract, of hops beta acid and less than 1%, by weight of the hops extract, of hops alpha acid.
  • the oral care composition can comprise 0.01% to about 10%, greater than 0.01% to about 10%, from about 0.05%, to about 10%, from about 0.1% to about 10%, from about 0.2% to about 10%, from about 0.2% to about 10%, from about 0.2% to about 5%, from about 0.25% to about 2%, from about 0.05% to about 2%, or from greater than 0.25% to about 2%, of hops extract, as described herein.
  • the oral care composition can comprise fluoride.
  • Fluoride can be provided by a fluoride ion source.
  • the fluoride ion source can comprise one or more fluoride containing compounds, such as stannous fluoride, sodium fluoride, titanium fluoride, calcium fluoride, calcium phosphate silicate fluoride, potassium fluoride, amine fluoride, sodium monofluorophosphate, zinc fluoride, and/or mixtures thereof.
  • the fluoride ion source and the tin ion source can be the same compound, such as for example, stannous fluoride, which can generate tin ions and fluoride ions. Additionally, the fluoride ion source and the tin ion source can be separate compounds, such as when the tin ion source is stannous chloride and the fluoride ion source is sodium monofluorophosphate or sodium fluoride.
  • the fluoride ion source and the zinc ion source can be the same compound, such as for example, zinc fluoride, which can generate zinc ions and fluoride ions. Additionally, the fluoride ion source and the zinc ion source can be separate compounds, such as when the zinc ion source is zinc phosphate and the fluoride ion source is stannous fluoride.
  • the fluoride ion source can be essentially free of, substantially free of, or free of stannous fluoride.
  • the oral care composition can comprise sodium fluoride, potassium fluoride, amine fluoride, sodium monofluorophosphate, zinc fluoride, and/or mixtures thereof.
  • the oral care composition can comprise a fluoride ion source capable of providing from about 50 ppm to about 5000 ppm, and preferably from about 500 ppm to about 3000 ppm of free fluoride ions.
  • the fluoride ion source may be present in the oral care composition at an amount of from about 0.0025% to about 5%, from about 0.01% to about 10%, from about 0.2% to about 1%, from about 0.5% to about 1.5%, or from about 0.3% to about 0.6%, by weight of the oral care composition.
  • the oral care composition can comprise less than 0.1%, less than 0.01%, be essentially free of, be substantially free of, or free of a fluoride ion source.
  • a subtherapeutic amount of a fluoride ion source for the purposes of anticaries activity can include an oral care composition comprising less than 1100 ppm, less than 800 ppm, less than 650 ppm, less than 500 ppm, equal to and less than 500 ppm, less than 250 ppm, equal to and less than 250 ppm, and/or combinations thereof.
  • a subtherapeutic amount of a fluoride ion source has a measurable anticaries affect, such as at least a 5%, at least a 7.5%, at least a 10%, at least a 15%, at least a 20%, and/or combinations thereof, but not a therapeutic anticaries effect as required by a regulatory agency in any jurisdiction of interest, as described further herein.
  • the oral care composition of the present invention can comprise tin, such as from a tin ion source.
  • the tin ion source can be any suitable compound that can provide tin ions in an oral care composition and/or deliver tin ions to the oral cavity when the dentifrice composition is applied to the oral cavity.
  • the tin ion source can comprise one or more tin containing compounds, such as stannous fluoride, stannous chloride, stannous bromide, stannous iodide, stannous oxide, stannous oxalate, stannous sulfate, stannous sulfide, stannic fluoride, stannic chloride, stannic bromide, stannic iodide, stannic sulfide, and/or mixtures thereof.
  • Tin ion source can comprise stannous fluoride, stannous chloride, and/or mixture thereof.
  • the tin ion source can also be a fluoride-free tin ion source, such as stannous chloride.
  • the oral care composition can comprise from about 0.0025% to about 5%, from about 0.01% to about 10%, from about 0.2% to about 1%, from about 0.5% to about 1.5%, or from about 0.3% to about 0.6%, by weight of the oral care composition, of a tin ion source.
  • the oral care composition of the present invention can comprise calcium, such as from a calcium ion source.
  • the calcium ion source can be any suitable compound or molecule that can provide calcium ions in an oral care composition and/or deliver calcium ions to the oral cavity when the oral care composition is applied to the oral cavity.
  • the calcium ion source can comprise a calcium salt, a calcium abrasive, and/or combinations thereof.
  • a calcium salt may also be considered a calcium abrasive or a calcium abrasive may also be considered a calcium salt.
  • the calcium ion source can comprise a calcium abrasive.
  • the calcium abrasive can be any suitable abrasive compound that can provide calcium ions in an oral care composition and/or deliver calcium ions to the oral cavity when the oral care composition is applied to the oral cavity.
  • the calcium abrasive can comprise one or more calcium abrasive compounds, such as calcium carbonate, precipitated calcium carbonate (PCC), ground calcium carbonate (GCC), chalk, dicalcium phosphate, calcium pyrophosphate, and/or mixtures thereof.
  • the calcium ion source can comprise a calcium salt, or a compound that can provide calcium ions in an oral care composition and/or deliver calcium ions to the oral cavity when the oral care composition is applied to the oral cavity that can not act as an abrasive.
  • the calcium salt can comprise one or more calcium compounds, such as calcium chloride, calcium nitrate, calcium phosphate, calcium lactate, calcium oxalate, calcium oxide, calcium gluconate, calcium citrate, calcium bromide, calcium iodate, calcium iodide, hydroxyapatite, fluorapatite, calcium sulfate, calcium glycerophosphate, and/or combinations thereof.
  • the calcium ion source can have a iPUM-Ca of at least 2 times, at least 4 times, at least 6 times of the iPUM-Ca of untreated biofilm as described herein.
  • the oral care composition can comprise from about 5% to about 70%, from about 10% to about 50%, from about 10% to about 60%, from about 20% to about 50%, from about 25% to about 40%, or from about 1% to about 50% of a calcium ion source.
  • the oral care composition can comprise a buffering agent.
  • the buffering agent can be a weak acid or base that can maintain a particular pH at a selected site in the oral cavity.
  • the buffering agent can maintain a pH at a tooth's surface to mitigate the impact of plaque acids produced by bacteria.
  • the buffering agent can comprise a conjugate acid of an ion also present in the oral care composition.
  • the buffering agent can comprise a bicarbonate anion (—HCO 3 ⁇ ).
  • the buffering agent can comprise a conjugate acid/base pair, such as citric acid and sodium citrate.
  • Suitable buffering systems can include phosphate, citrate salts, carbonate/bicarbonate salts, a tris buffer, imidazole, urea, borate, and/or combinations thereof.
  • Suitable buffering agents include bicarbonate salts, such as sodium bicarbonate, glycine, orthophosphate, arginine, urea, and or/combinations thereof.
  • the oral care composition can comprise from about 0.5% to about 30%, from about 5% to about 25% or from about 10% to about 20%, of one or more buffering agents.
  • the oral care composition can comprise one or more biofilm modifiers.
  • a biofilm modifier can comprise a polyol, an ammonia generating compound, and/or a glucosyltransferase inhibitor.
  • a polyol is an organic compound with more than one hydroxyl functional groups.
  • the polyol can be any suitable compound that can weakly associate, interact, or bond to tin ions while the oral care composition is stored prior to use.
  • the polyol can be a sugar alcohol, which area class of polyols that can be obtained through the hydrogenation of sugar compounds with the formula (CHOH) n H 2 .
  • the polyol can be glycerin, erythritol, xylitol, sorbitol, mannitol, butylene glycol, lactitol, and/or combinations thereof.
  • the oral care composition can comprise 0.01% to about 70%, from about 5% to about 70%, from about 5% to about 50%, from about 10% to about 60%, from about 10% to about 25%, or from about 20% to about 80%, by weight of the oral care composition, of a polyol.
  • the ammonia generating compound can be any suitable compound that can generate ammonia upon delivery to the oral cavity. Suitable ammonia generating compounds include arginine, urea, and/or combinations thereof.
  • the oral care composition can comprise from about 0.01% to about 10%, from about 1% to about 5%, or from about 1% to about 25% of one or more ammonia generating compounds.
  • the glucosyltransferase inhibitor can be any suitable compound that can inhibit a glucosyltransferase.
  • Glucosyltransferases are enzymes that can establish natural glycosidic linkages. In particular, these enzymes break down poly- or oligosaccharide moieties into simple sugars for bacteria associated with dental caries. As such, any compound that can inhibit this process can help prevent dental caries.
  • Suitable glucosyltransferase inhibitors include oleic acid, epicatechin, tannins, tannic acid, moenomycin, caspofungin, ethambutol, lufenuron, and/or combinations thereof.
  • the oral care composition can comprise from about 0.001% to about 5%, from about 0.01% to about 2%, or about 1% of one or more glucosyltransferase inhibitors.
  • the oral care composition can comprise metal, such as from a metal ion source comprising one or more metal ions.
  • the metal ion source can comprise or be in addition to the tin ion source and/or the zinc ion source, as described herein.
  • Suitable metal ion sources include compounds with metal ions, such as, but not limited to Sn, Zn, Cu, Mn, Mg, Sr, Ti, Fe, Mo, B, Ba, Ce, Al, In and/or mixtures thereof.
  • the trace metal source can be any compound with a suitable metal and any accompanying ligands and/or anions.
  • Suitable ligands and/or anions that can be paired with metal ion sources include, but are not limited to acetate, ammonium sulfate, benzoate, bromide, borate, carbonate, chloride, citrate, gluconate, glycerophosphate, hydroxide, iodide, oxide, propionate, D-lactate, DL-lactate, orthophosphate, pyrophosphate, sulfate, nitrate, tartrate, and/or mixtures thereof.
  • the oral care composition can comprise from about 0.01% to about 10%, from about 1% to about 5%, or from about 0.5% to about 15% of a metal ion source.
  • the oral care composition can also include bioactive materials suitable for the remineralization of a tooth.
  • Suitable bioactive materials include bioactive glasses, NovaminTM, RecaldentTM, hydroxyapatite, one or more amino acids, such as, for example, arginine, citrulline, glycine, lysine, or histidine, or combinations thereof.
  • suitable examples of compositions comprising arginine are found in U.S. Pat. Nos. 4,154,813 and 5,762,911, which are herein incorporated by reference in their entirety.
  • Other suitable bioactive materials include any calcium phosphate compound.
  • Other suitable bioactive materials include compounds comprising a calcium source and a phosphate source.
  • Amino acids are organic compounds that contain an amine functional group, a carboxyl functional group, and a side chain specific to each amino acid. Suitable amino acids include, for example, amino acids with a positive or negative side chain, amino acids with an acidic or basic side chain, amino acids with polar uncharged side chains, amino acids with hydrophobic side chains, and/or combinations thereof.
  • Suitable amino acids also include, for example, arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, glycine, proline, alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, tryptophan, citrulline, ornithine, creatine, diaminobutonic acid, diaminoproprionic acid, salts thereof, and/or combinations thereof.
  • Bioactive glasses are comprising calcium and/or phosphate which can be present in a proportion that is similar to hydroxyapatite. These glasses can bond to the tissue and are biocompatible. Bioactive glasses can include a phosphopeptide, a calcium source, phosphate source, a silica source, a sodium source, and/or combinations thereof.
  • the oral care composition can comprise from about 0.01% to about 20%, from about 0.1% to about 10%, or from about 1% to about 10% of a bioactive material by weight of the oral care composition.
  • the oral care composition can comprise a calcium abrasive, as described herein, and/or a non-calcium abrasive, such as bentonite, silica gel (by itself, and of any structure), precipitated silica, amorphous precipitated silica (by itself, and of any structure as well), hydrated silica, perlite, titanium dioxide, calcium pyrophosphate, dicalcium phosphate dihydrate, alumina, hydrated alumina, calcined alumina, aluminum silicate, insoluble sodium metaphosphate, insoluble potassium metaphosphate, insoluble magnesium carbonate, zirconium silicate, particulate thermosetting resins and other suitable abrasive materials.
  • a calcium abrasive as described herein, and/or a non-calcium abrasive, such as bentonite, silica gel (by itself, and of any structure), precipitated silica, amorphous precipitated silica (by itself, and of any structure as well), hydrated si
  • the oral care composition can comprise from about 5% to about 70%, from about 10% to about 50%, from about 10% to about 60%, from about 20% to about 50%, from about 25% to about 40%, or from about 1% to about 50%, by weight of the oral care composition, of the non-calcium abrasive.
  • the oral care composition can be substantially free of, essentially free of, or free of silica, alumina, or any other non-calcium abrasive.
  • the oral care composition can comprise less than about 5%, less than about 1%, less than about 0.5%, less than about 0.1%, or 0% of a non-calcium abrasive, such as silica and/or alumina.
  • the oral care composition of the present invention can be anhydrous, a low water formulation, or a high water formulation.
  • the oral care composition can comprise from 0% to about 99%, from about 5% to about 75%, about 20% or greater, about 30% or greater, or about 50% or greater by weight of the composition, of water.
  • the water is USP water.
  • the oral care composition comprises from about 45% to about 75%, by weight of the composition, of water.
  • the high water oral care composition and/or toothpaste formulation can comprise from about 45% to about 65%, from about 45% to about 55%, or from about 46% to about 54%, by weight of the composition, of water.
  • the water may be added to the high water formulation and/or may come into the composition from the inclusion of other ingredients.
  • the oral care composition comprises from about 5% to about 45%, by weight of the composition, of water.
  • the low water oral care composition can comprise from about 5% to about 35%, from about 10% to about 25%, or from about 20% to about 25%, by weight of the composition, of water.
  • the water may be added to the low water formulation and/or may come into the composition from the inclusion of other ingredients.
  • the oral care composition comprises less than about 10%, by weight of the composition, of water.
  • the anhydrous composition comprises less than about 5%, less than about 1%, or 0%, by weight of the composition, of water.
  • the water may be added to the anhydrous formulation and/or may come into the composition from the inclusion of other ingredients.
  • a mouth rinse formulation comprises from about 75% to about 99%, from about 75% to about 95%, or from about 80% to about 95% of water.
  • composition can also comprise other orally acceptable carrier materials, such as alcohol, humectants, polymers, surfactants, and acceptance improving agents, such as flavoring, sweetening, coloring and/or cooling agents.
  • carrier materials such as alcohol, humectants, polymers, surfactants, and acceptance improving agents, such as flavoring, sweetening, coloring and/or cooling agents.
  • the pH of the disclosed composition can be from about 4 to about 10, from about 7 to about 10, greater than 7 to about 10, greater than 8 to about 10, greater than 7, greater than 7.5, greater than 8, greater than 9, or from about 8.5 to about 10.
  • the oral care composition can comprise zinc, such as from a zinc ion source.
  • the zinc ion source can comprise one or more zinc containing compounds, such as zinc fluoride, zinc lactate, zinc oxide, zinc phosphate, zinc chloride, zinc acetate, zinc hexafluorozirconate, zinc sulfate, zinc tartrate, zinc gluconate, zinc citrate, zinc malate, zinc glycinate, zinc pyrophosphate, zinc metaphosphate, zinc oxalate, and/or zinc carbonate.
  • the zinc ion source can be a fluoride-free zinc ion source, such as zinc phosphate, zinc oxide, and/or zinc citrate.
  • the zinc ion source may be present in the total oral care composition at an amount of from about 0.01% to about 10%, from about 0.2% to about 1%, from about 0.5% to about 1.5%, or from about 0.3% to about 0.6%, by weight of the dentifrice composition.
  • the oral care composition can comprise polyphosphate, such as from a polyphosphate source.
  • a polyphosphate source can comprise one or more polyphosphate molecules.
  • Polyphosphates are a class of materials obtained by the dehydration and condensation of orthophosphate to yield linear and cyclic polyphosphates of varying chain lengths. Thus, polyphosphate molecules are generally identified with an average number (n) of polyphosphate molecules, as described below.
  • a polyphosphate is generally understood to consist of two or more phosphate molecules arranged primarily in a linear configuration, although some cyclic derivatives may be present.
  • Preferred polyphosphates are those having an average of two or more phosphate groups so that surface adsorption at effective concentrations produces sufficient non-bound phosphate functions, which enhance the anionic surface charge as well as hydrophilic character of the surfaces.
  • Preferred in this invention are the linear polyphosphates having the formula: XO(XPO 3 ) n X, wherein X is sodium, potassium, ammonium, or any other alkali metal cations and n averages from about 2 to about 21.
  • Alkali earth metal cations, such as calcium, are not preferred because they tend to form insoluble fluoride salts from aqueous solutions comprising a fluoride ions and alkali earth metal cations.
  • the oral care compositions disclosed herein can be free of, essentially free of, or substantially free of calcium pyrophosphate.
  • Polyphosphates can include those polyphosphate compounds manufactured by FMC Corporation, ICL Performance Products, and/or Astaris.
  • the oral care composition can comprise from about 0.01% to about 15%, from about 0.1% to about 10%, from about 0.5% to about 5%, from about 1 to about 20%, or about 10% or less, by weight of the oral care composition, of the polyphosphate source.
  • the oral care composition can comprise one or more humectants, have low levels of a humectant, be substantially free of, substantially free of, or be free of a humectant.
  • Humectants serve to add body or “mouth texture” to an oral care composition or dentifrice as well as preventing the dentifrice from drying out.
  • Suitable humectants include polyethylene glycol (at a variety of different molecular weights), propylene glycol, glycerin (glycerol), erythritol, xylitol, sorbitol, mannitol, butylene glycol, lactitol, hydrogenated starch hydrolysates, and/or mixtures thereof.
  • the oral care composition can comprise one or more humectants each at a level of from 0 to about 70%, from about 5% to about 50%, from about 10% to about 60%, or from about 20% to about 80%, by weight of the oral care composition.
  • the oral care composition can comprise one or more surfactants.
  • the surfactants can be used to make the compositions more cosmetically acceptable.
  • the surfactant is preferably a detersive material which imparts to the composition detersive and foaming properties.
  • Suitable surfactants are safe and effective amounts of anionic, cationic, nonionic, zwitterionic, amphoteric and betaine surfactants.
  • Suitable anionic surfactants include, for example, the water soluble salts of alkyl sulfates having from 8 to 20 carbon atoms in the alkyl radical and the water-soluble salts of sulfonated monoglycerides of fatty acids having from 8 to 20 carbon atoms.
  • Sodium lauryl sulfate (SLS) and sodium coconut monoglyceride sulfonates are examples of anionic surfactants of this type.
  • anionic surfactants include sarcosinates, such as sodium lauroyl sarcosinate, taurates, sodium lauryl sulfoacetate, sodium lauroyl isethionate, sodium laureth carboxylate, and sodium dodecyl benzene sulfonate. Combinations of anionic surfactants can also be employed.
  • alkyl phosphates Another suitable class of anionic surfactants are alkyl phosphates.
  • the surface active organophosphate agents can have a strong affinity for enamel surface and have sufficient surface binding propensity to desorb pellicle proteins and remain affixed to enamel surfaces.
  • Suitable examples of organophosphate compounds include mono-, di- or triesters represented by the general structure below wherein Z 1 , Z 2 , or Z 3 may be identical or different with at least one being an organic moiety.
  • Z 1 , Z 2 , or Z 3 can be selected from linear or branched, alkyl or alkenyl group of from 1 to 22 carbon atoms, optionally substituted by one or more phosphate groups; alkoxylated alkyl or alkenyl, (poly)saccharide, polyol or polyether group.
  • alkyl or alkenyl phosphate esters represented by the following structure:
  • R 1 represents a linear or branched, alkyl or alkenyl group of from 6 to 22 carbon atoms, optionally substituted by one or more phosphate groups; n and m, are individually and separately, 2 to 4, and a and b, individually and separately, are 0 to 20; Z and Z may be identical or different, each represents hydrogen, alkali metal, ammonium, protonated alkyl amine or protonated functional alkylamine, such as analkanolamine, or a R—(OCH2)(OCH)— group.
  • alkyl and alkyl (poly)alkoxy phosphates such as lauryl phosphate; PPGS ceteareth-10 phosphate; laureth-1 phosphate; laureth-3 phosphate; laureth-9 phosphate; trilaureth-4 phosphate; C 12-18 PEG 9 phosphate: and sodium dilaureth-10 phosphate.
  • the alkyl phosphate can be polymeric.
  • polymeric alkyl phosphates include those containing repeating alkoxy groups as the polymeric portion, in particular 3 or more ethoxy, propoxy isopropoxy or butoxy groups.
  • Suitable anionic surfactants are sarcosinates, isethionates and taurates, especially their alkali metal or ammonium salts. Examples include: lauroyl sarcosinate, myristoyl sarcosinate, palmitoyl sarcosinate, stearoyl sarcosinate oleoyl sarcosinate, or combinations thereof.
  • anionic surfactants include sodium or potassium alkyl sulfates, such as sodium lauryl sulfate, acyl isethionates, acyl methyl isethionates, alkyl ether carboxylates, acyl alaninates, acyl gulatames, acyl glycinates, acyl sarconsinates, sodium methyl acyl taurates, sodium laureth sulfosuccinates, alpha olefin sulfonates, alkyl benze sulfonates, sodium lauroyl lactylate, sodium laurylglucosides hydroxypropyl sulfonate, and/or combinations.
  • alkyl sulfates such as sodium lauryl sulfate, acyl isethionates, acyl methyl isethionates, alkyl ether carboxylates, acyl alaninates, acyl gulat
  • Zwitterionic or amphoteric surfactants useful herein include derivatives of aliphatic quaternary ammonium, phosphonium, and Sulfonium compounds, in which the aliphatic radicals can be straight chain or branched, and one of the aliphatic substituents contains from 8 to 18 carbon atoms and one contains an anionic water-solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate or phosphonate.
  • Suitable betaine surfactants are disclosed in U.S. Pat. No. 5,180,577.
  • Typical alkyl dimethyl betaines include decyl betaine or 2-(N-decyl-N,N-dimethylammonio) acetate, coco-betaine or 2-(N-coco-N,N-dimethyl ammonio)acetate, myristyl betaine, palmityl betaine, lauryl betaine, cetyl betaine, cetyl betaine, stearyl betaine, etc.
  • the amidobetaines can be exemplified by cocoamidoethyl betaine, cocoamidopropyl betaine (CADB), and lauramidopropyl betaine.
  • Other suitable amphoteric surfactants include betaines, sultaines, sodium laurylamphoacetates, alkylamphodiacetates, and/or combinations thereof.
  • Cationic surfactants useful in the present invention include, for example, derivatives of quaternary ammonium compounds having one long alkyl chain containing from 8 to 18 carbon atoms such as lauryl trimethylammonium chloride; cetyl pyridinium chloride; cetyl trimethyl-ammonium bromide; cetyl pyridinium fluoride or combinations thereof.
  • Nonionic surfactants that can be used in the compositions of the present invention include, for example, compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkylaromatic in nature.
  • suitable nonionic surfactants can include the Pluronics® which are poloxamers, polyethylene oxide condensates of alkyl phenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine, ethylene oxide condensates of aliphatic alcohols, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides and combinations of such materials.
  • Other suitable non-ionic surfactants includes alkyl glucamides, alkyl glucosides, and/or combinations thereof.
  • the one or more surfactants can also include one or more natural and/or naturally derived surfactants.
  • Natural surfactants can include surfactants that are derived from natural products and/or surfactants that are minimally or not processed. Natural surfactants can include hydrogenated, non-hydrogenated, or partially hydrogenated vegetable oils, olus oil, passiflora incarnata oil, candelilla cera, coco-caprylate, caprate, dicaprylyl ether, lauryl alcohol, myristyl myristate, dicaprylyl ether, caprylic acid, caprylic ester, octyl decanoate, octyl octanoate, undecane, tridecane, decyl oleate, oleic acid decylester, cetyl palmitate, stearic acid, palmitic acid, glyceryl stearate, hydrogenated, non-hydrogenated, or partially hydrogenated vegetable glycerides, Poly
  • Natural surfactants can include any of the Natrue ingredients marketed by BASF, such as, for example, CegeSoft®, Cetiol®, Cutina®, Dehymuls®, Emulgade®, Emulgin®, Eutanol®, Gluadin®, Lameform®, LameSoft®, Lanette®, Monomuls®, Myritol®, Plantacare®, Plantaquat®, Platasil®, Rheocare®, Sulfopon®, Texapon®, and/or combinations thereof.
  • CegeSoft® Cetiol®
  • Cutina® Cutina®
  • Dehymuls® Emulgade®
  • Emulgin® Eutanol®
  • Gluadin® Lameform®
  • LameSoft® Lanette®
  • Monomuls® Monomuls®
  • Myritol® Plantacare®
  • Plantaquat® Plantaquat®
  • Platasil® R
  • surfactants include sodium lauryl sulfate, sodium lauryl isethionate, sodium lauroyl methyl isethionate, sodium cocoyl glutamate, sodium dodecyl benzene sulfonate, alkali metal or ammonium salts of lauroyl sarcosinate, myristoyl sarcosinate, palmitoyl sarcosinate, stearoyl sarcosinate and oleoyl sarcosinate, polyoxyethylene sorbitan monostearate, isostearate and laurate, sodium lauryl sulfoacetate, N-lauroyl sarcosine, the sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine, polyethylene oxide condensates of alkyl phenols, cocoamidopropyl betaine, lauramidopropyl
  • the oral care composition can comprise one or more surfactants each at a level from about 0.01% to about 15%, from about 0.3% to about 10%, or from about 0.3% to about 2.5%, by weight of the oral care composition.
  • the oral care composition can comprise one or more thickening agents.
  • Thickening agents can be useful in the oral care compositions to provide a gelatinous structure that stabilizes the dentifrice and/or toothpaste against phase separation.
  • Suitable thickening agents include polysaccharides, polymers, and/or silica thickeners.
  • the thickening agent can comprise one or more polysaccharides.
  • polysaccharides include starch; glycerite of starch; gums such as gum karaya (sterculia gum), gum tragacanth, gum arabic, gum ghatti, gum acacia, xanthan gum, guar gum and cellulose gum; magnesium aluminum silicate (Veegum); carrageenan; sodium alginate; agar-agar; pectin; gelatin; cellulose compounds such as cellulose, microcrystalline cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxymethyl carboxypropyl cellulose, methyl cellulose, ethyl cellulose, and sulfated cellulose; natural and synthetic clays such as hectorite clays; and mixtures thereof.
  • Carageenans is a polysaccharide derived from seaweed. There are several types of carageenan that may be distinguished by their seaweed source and/or by their degree of and position of sulfation.
  • the thickening agent can comprise kappa carageenans, modified kappa carageenans, iota carageenans, modified iota carageenans, lambda carrageenan, and mixtures thereof.
  • Carageenans suitable for use herein include those commercially available from the FMC Company under the series designation “Viscarin,” including but not limited to Viscarin TP 329, Viscarin TP 388, and Viscarin TP 389.
  • the thickening agent can comprise one or more polymers.
  • the polymer can be a polyethylene glycol (PEG), a polyvinylpyrrolidone (PVP), polyacrylic acid, a polymer derived from at least one acrylic acid monomer, a copolymer of maleic anhydride and methyl vinyl ether, a crosslinked polyacrylic acid polymer, of various weight percentages of the oral care composition as well as various ranges of average molecular ranges.
  • the oral care composition can be free of, substantially free of, or essentially free of a copolymer of maleic anhydride and methyl vinyl ether.
  • the thickening agent can comprise one or more inorganic thickening agents.
  • suitable inorganic thickening agents include colloidal magnesium aluminum silicate, silica thickeners.
  • Useful silica thickeners include, for example, include, as a non-limiting example, an amorphous precipitated silica such as ZEODENT® 165 silica.
  • Other non-limiting silica thickeners include ZEODENT® 153, 163, and 167, and ZEOFREE® 177 and 265 silica products, all available from Evonik Corporation, and AEROSIL® fumed silicas.
  • the oral care composition can comprise from 0.01% to about 15%, from 0.1% to about 10%, from about 0.2% to about 5%, or from about 0.5% to about 2% of one or more thickening agents.
  • the oral care composition of the present invention can comprise prenylated flavonoid.
  • Flavonoids are a group of natural substances found in a wide range of fruits, vegetables, grains, bark, roots, stems, flowers, tea, and wine. Flavonoids can have a variety of beneficial effects on health, such as antioxidative, anti-inflammatory, antimutagenic, anticarcinogenic, and antibacterial benefits.
  • Prenylated flavonoids are flavonoids that include at least one prenyl functional group (3-methylbut-2-en-1-yl, as shown in Formula VIII), which has been previously identified to facilitate attachment to cell membranes.
  • prenyl group i.e.
  • prenylation, to a flavonoid can increase the activity of the original flavonoid by increasing the lipophilicity of the parent molecule and improving the penetration of the prenylated molecule into the bacterial cell membrane.
  • Increasing the lipophilicity to increase penetration into the cell membrane can be a double-edged sword because the prenylated flavonoid will tend towards insolubility at high Log P values (high lipophilicity).
  • Log P can be an important indicator of antibacterial efficacy.
  • prenylated flavonoids can include flavonoids found naturally with one or more prenyl functional groups, flavonoids with a synthetically added prenyl functional group, and/or prenylated flavonoids with additional prenyl functional groups synthetically added.
  • Suitable functionalities of the parent molecule that improve the structure-activity relationship (e.g,. structure-MIC relationship) of the prenylated molecule include additional heterocycles containing nitrogen or oxygen, alkylamino chains, or alkyl chains substituted onto one or more of the aromatic rings of the parent flavonoid.
  • Flavonoids can have a 15-carbon skeleton with at least two phenyl rings and at least one heterocyclic ring.
  • Some suitable flavonoid backbones can be shown in Formula IX (flavone backbone), Formula X (isoflavan backbone), and/or Formula XI (neoflavonoid backbone).
  • flavonoids include anthocyanidins, anthoxanthins, flavanones, flavanonols, flavans, isoflavonoids, chalcones and/or combinations thereof.
  • Prenylated flavonoids can include naturally isolated prenylated flavonoids or naturally isolated flavonoids that are synthetically altered to add one or more prenyl functional groups through a variety of synthetic processes that would be known to a person of ordinary skill in the art of synthetic organic chemistry.
  • prenylated flavonoids can include Bavachalcone, Bavachin, Bavachinin, Corylifol A, Epimedin A, Epimedin A1, Epimedin B, Epimedin C, Icariin, Icariside I, Icariside II, Icaritin, Isobavachalcone, Isoxanthohumol, Neobavaisoflavone, 6-Prenylnaringenin, 8-Prenylnaringenin, Sophoraflavanone G, ( ⁇ )-Sophoranone, Xanthohumol, Quercetin, Macelignan, Kuraridin, Kurarinone, Kuwanon G, Kuwanon C, Panduratin A, 6-geranylnaringenin, Australone A, 6,8-Diprenyleriodictyol, dorsmanin C, dorsmanin F, 8-Prenylkaempferol, 7-O-Methyll
  • the prenylated flavonoid has a high probability of having an MIC of less than about 25 ppm for S. aureus, a gram-positive bacterium.
  • Suitable prenylated flavonoids include Bavachin, Bavachinin, Corylifol A, Icaritin, Isoxanthohumol, Neobavaisoflavone, 6-Prenylnaringenin, 8-Prenylnaringenin, Sophoraflavanone G, ( ⁇ )-Sophoranone, Kurarinone, Kuwanon C, Panduratin A, and/or combinations thereof.
  • the prenylated flavonoid has a high probability of having an MIC of less than about 25 ppm for E. coli, a gram-negative bacterium.
  • Suitable prenylated flavonoids include Bavachinin, Isoxanthohumol, 8-Prenylnaringenin, Sophoraflavanone G, Kurarinone, Panduratin A, and/or combinations thereof.
  • prenylated flavonoids Approximately 1000 prenylated flavonoids have been identified from plants. According to the number of prenylated flavonoids reported before, prenylated flavonones are the most common subclass and prenylated flavanols is the rarest sub-class. Even though natural prenylated flavonoids have been detected to have diversely structural characteristics, they have a narrow distribution in plants, which are different to the parent flavonoids as they are present almost in all plants. Most of prenylated flavonoids are found in the following families, including Cannabaceae, Guttiferae, Leguminosae, Moraceae, Rutaceae and Umbelliferae.
  • Humulus lupulus of the Cannabaceae include 8-prenylnaringenin and xanthohumol, which play an important role in the health benefits of beer.
  • the prenylated flavonoid can be incorporated through the hops extract, incorporated in a separately added extract, or added as a separate component of the oral care compositions disclosed herein.
  • the oral care composition can comprise a variety of other ingredients, such as flavoring agents, sweeteners, colorants, preservatives, buffering agents, or other ingredients suitable for use in oral care compositions, as described below.
  • Flavoring agents also can be added to the oral care composition. Suitable flavoring agents include oil of wintergreen, oil of peppermint, oil of spearmint, clove bud oil, menthol, anethole, methyl salicylate, eucalyptol, cassia, 1-menthyl acetate, sage, eugenol, parsley oil, oxanone, alpha-irisone, marjoram, lemon, orange, propenyl guaethol, cinnamon, vanillin, ethyl vanillin, heliotropine, 4-cis-heptenal, diacetyl, methyl-para-tert-butyl phenyl acetate, and mixtures thereof.
  • Coolants may also be part of the flavor system.
  • Preferred coolants in the present compositions are the paramenthan carboxyamide agents such as N-ethyl-p-menthan-3-carboxamide (known commercially as “WS-3”) or N-(Ethoxycarbonylmethyl)-3-p-menthanecarboxamide (known commercially as “WS-5”), and mixtures thereof.
  • a flavor system is generally used in the compositions at levels of from about 0.001% to about 5%, by weight of the oral care composition.
  • These flavoring agents generally comprise mixtures of aldehydes, ketones, esters, phenols, acids, and aliphatic, aromatic and other alcohols.
  • Sweeteners can be added to the oral care composition to impart a pleasing taste to the product.
  • Suitable sweeteners include saccharin (as sodium, potassium or calcium saccharin), cyclamate (as a sodium, potassium or calcium salt), acesulfame-K, thaumatin, neohesperidin dihydrochalcone, ammoniated glycyrrhizin, dextrose, levulose, sucrose, mannose, sucralose, stevia, and glucose.
  • Colorants can be added to improve the aesthetic appearance of the product. Suitable colorants include without limitation those colorants approved by appropriate regulatory bodies such as the FDA and those listed in the European Food and Pharmaceutical Directives and include pigments, such as TiO 2 , and colors such as FD&C and D&C dyes.
  • Preservatives also can be added to the oral care compositions to prevent bacterial growth.
  • Suitable preservatives approved for use in oral compositions such as methylparaben, propylparaben, benzoic acid, and sodium benzoate can be added in safe and effective amounts.
  • Titanium dioxide may also be added to the present composition. Titanium dioxide is a white powder which adds opacity to the compositions. Titanium dioxide generally comprises from about 0.25% to about 5%, by weight of the oral care composition.
  • ingredients can be used in the oral care composition, such as desensitizing agents, healing agents, other caries preventative agents, chelating/sequestering agents, vitamins, amino acids, proteins, other anti-plaque/anti-calculus agents, opacifiers, antibiotics, anti-enzymes, enzymes, pH control agents, oxidizing agents, antioxidants, and the like.
  • the fluoride content in the rat caries treatment slurries can be estimated using the ADA One-Minute Release method.
  • the exact methodology is maintained by the ADA as part of its seal acceptance program and is available from the Association. An outline of the method as used herein is described below.
  • the ADA also references the ANSI/ADA Standard No. 116 Oral Rinses or ISO 16408 Dentistry—Oral Hygiene Products—Oral Rinses for an example ion-selective electrode method for determining the ionic fluoride content in oral care products.
  • a stock fluoride solution (0.5 mg/mL, 500 ppm, Ricca, RC3172-16, Arlington, Tex.) was diluted to make solutions of 5 ppm, 25 ppm, 50 ppm, and 250 ppm using deionized water. Each standard was diluted at a 1:1 ratio with TISAB II (Ricca, Arlington, Tex.) buffer solution to create calibration solutions (TISAB IV (Ricca, Arlington, Tex.) if the calibration solutions are intended for stannous fluoride samples).
  • a calibration curve was created using the calibration solutions. 200 ⁇ L of 25 ppm calibration solution was placed in a microsample cup. A fluoride electrode (VWR, Radnor, Pa.) was placed in the solution and the mV of each sample is noted by reading the electrode meter (VWR, Radnor, Pa.). The procedure was repeated for each prepared calibration solution. A calibration curve was constructed by plotting mV vs. Log [F-].
  • Paste dentifrice samples were prepared by weighing approximately 4 g of each paste sample in a 70 mL speed mixer cup. Next, 12 mL of deionized was added to the sample cup. The speed mixer cup was mixed for 60 seconds (FlackTek Speedmixer, Landrum, S.C.) using Speedmixer Program #7, which is 800 rpm for 5 seconds and then 2200 rpm for 55 seconds. The slurry samples were transferred into a centrifuge tube and then centrifuged for 10 minutes at 11,000 rpm.
  • Samples were prepared for analysis by combining 1 mL of the supernatant and 1 mL of fresh TISAB II buffer for sodium fluoride samples and TISAB IV for stannous fluoride samples. The samples were quickly mixed using a vortex mixer. 200 ⁇ L of the solution were transferred to a micro sample cup. The fluoride electrode was placed in the cap. The value (mV) was recorded.
  • IRM Insoluble Raw Materials
  • the ADA one-minute fluoride release was estimated based on the recorded formulated fluoride content, fluoride source, and abrasive combination.
  • the formulated fluoride content was used when it is known to closely correspond to the ADA one-minute fluoride release results, i.e., for Crest® Cavity Protection.
  • MFP-containing toothpastes additional steps were needed to liberate the fluoride ion such that it could be measured by an ion selective electrode. The steps were the same up to isolation of the supernatant. Following supernatant isolation, a 1.5 mL aliquot of the MFP-containing supernatant was combined with 2.5 mL of 2N hydrochloric acid (VWR, Radnor, Pa.) in an airtight tube that was caped tightly and mixed vigorously for 30 seconds. The tube headspace was minimized as much as possible. It was then heated to 50° C. for 20 minutes and cooled to room temperature at ambient, benchtop conditions.
  • VWR 2N hydrochloric acid
  • Successful demonstration of an analyst's ability to execute the method can be demonstrated by achieving an ADA fluoride released between about 95% to 100% for the USP NaF/Silica toothpaste or for about 70% to about 85% for the USP SnF 2 /Silica toothpaste.
  • the coefficient of correlation for the F calibration curve on the ion selective electrode should be 0.995 or higher. Verify the accuracy by running check standards that bracket the results before and after sample readings.
  • the in vitro plaque glycolysis model is a technique in which plaque is grown from human saliva and treated with various agents to determine anti-glycolytic activity of treatments. When bacteria convert sugar into energy with the help of enzymes, acids are formed. These acids demineralize and damage the dental enamel.
  • the purpose of this technique is to provide a simple method for determining if treatment compounds have an inhibitory effect on the metabolic pathways that plaque microorganisms utilize for the production of acids or toxins and/or inhibit their growth.
  • the test therapeutic compositions contain Sn
  • the Sn placebo should be tested or controlled for correctly.
  • the antibacterial composition should be tested with respect to its placebo to determine the iPGRM value for the antibacterial composition only. This is important if buffers, e.g., bicarbonate, orthophosphate, calcium carbonate, are present in the composition in addition to the antibacterial composition.
  • a plaque biofilm was grown on glass rods from fresh pooled human saliva and Trypticase Soy Broth (TSB) at 37° C. over 2 days by dipping glass rods into and out of media in a reciprocating motion using a rack suspended on a rod and moved by a reciprocating motor inside of an incubation oven. Treatments were 2 minutes of dentifrice slurry in water (1:5) or diluted treatment in water (1:5). After treatments, biofilms were incubated with TSB and sucrose until pH indicator showed a color change ( ⁇ 6 hrs). The pH of the media solutions was then measured to determine the amount of glycolysis inhibition relative to a negative control.
  • TSB Trypticase Soy Broth
  • new glass rods (5 mm ⁇ 90 mm) were polished approximately 25 mm from the un-tapered end on a lathe with silicon carbide paper of 240, 320, 400, and 600 grit used sequentially. After the initial polishing, the rods should be polished with 600 grit paper before each test. After polishing, rods were stored until ready to run. Enough rods should be polished for a full rack of treatments.
  • a rack can treat 12 compositions with 4 replicates of each composition such that the rack has 48 rods.
  • saliva was collected daily during the test from a panel of 5-10 people by paraffin stimulation and was refrigerated at 4° C. until it was needed throughout the day. Pool saliva carefully (do not pour in wax/mucus) and mix thoroughly before use. Saliva should be collected from panelists free from disease, who are not on any antibacterial medication or medication that modifies saliva flow, and who brush regularly with Crest Cavity Protection.
  • the rods were removed from storage, rinsed with deionized water to remove any sanding residue, disinfected in 70% ethanol/water solution, and were allowed to dry on a sterile surface. Subsequently, the rods were loaded into a hanging rack of holders that were used to dip the rods continuously into media vials containing growth media.
  • the rod heights were adjusted and each rod was secured in place using a rubber o-ring.
  • 7 mL of growth media 160 g of a solution of 3% TSB (VWR, Radnor, Pa.) with 3% sucrose (VWR, Radnor, Pa.) was mixed with 240 g pooled human saliva. This TSB/sucrose solution should be sterilized by autoclave before combining with the pooled human saliva.) into media vials.
  • the media vials were arranged under the hanging rods on a rack in an incubation oven.
  • the incubator has been previously modified such that a dipping motor can dip the rods into the media vials submerging 1.5 cm of the rod into the growth media at a frequency of 1 dip per minute without the rods touching the walls of the media vial.
  • the rods were dipped overnight this way.
  • an enriched growth media was prepared (500 g of a solution of 3% TSB and 10% sucrose was mixed with 33 g pooled human saliva. This TSB/sucrose solution should be sterilized by autoclave before combining with the pooled human saliva.).
  • This enriched growth media was pipetted into a new set of media vials (7 mL per vial) and was swapped for the overnight growth media from Day 1. The rods were dipped throughout the day in this enriched growth media for 5 hours at 37° C. in the incubation oven.
  • a new overnight growth media was prepared (40 g of a solution of 3% TSB was mixed with 360 g pooled human saliva and 0.5 g sucrose), pipetted into a new set of media vials, and swapped for the enriched growth media.
  • the rods were dipped overnight in the same fashion as on the first day.
  • a glycolysis media was prepared by combining 0.15 g TSB, 25 g sucrose, and 500 mL deionized water resulting in a solution of 0.03% TSB and 0.5% sucrose in water. This solution was mixed then sterilized in an autoclave. The pH was then adjusted to 6.5 using 0.1M HCl and pipetted into new media vials (7 mL). Two extra vials were filled than were needed for the rack of rods as pH blanks. Two drops of chlorophenol red solution were added to each of the 4 tubes that contained the glycolysis media for the negative control treatment group (Crest Cavity Protection slurry).
  • the biofilm on the rods not touch the walls of any of the media, treatment, or rinse vials that would result in the removal of biofilm.
  • the entire biofilm was treated and rinsed. Once all treatments were complete, the biofilms on the rods were fully submerged in the glycolysis media inside the incubation oven with no dipping for 2 hours. After two hours, the dipping apparatus was activated. The total incubation time was between 3 to 7 hours. Incubation is terminated when the pH value in the glycolysis media of the negative controls is between 4.8-5.6, more ideally 4.9-5.2, and when the pH value in the glycolysis media of the positive controls is above the negative control. If the indicator dye in the positive control turns yellow, i.e., the pH has dropped beneath 5.2, the incubation has gone on too long and the test will need to be repeated.
  • the rods were removed from the glycolysis media and allowed to dry in the oven.
  • the glycolysis media was removed from the incubation oven, allowed to return to room temperature, and the pH was measured in each vial and the blank vials to determine the average pH change of the media following treatment.
  • the change in pH is determined with respect to the blank vials. If the final pH of the blank is less than 6.6, the test needs to be repeated. If the difference between the positive and negative control is not significant in a student's t-test, the test needs to be repeated. If the change in pH of the negative control of the negative control with respect to the blank is less than 1, the test needs to be repeated.
  • the ⁇ pH per vial was determined by subtracting its pH from the average pH of the blanks.
  • the glycolysis inhibition efficacy is determined from the following formula.
  • the average ⁇ pH of a treatment was determined by averaging the results from the four replicate vials per treatment.
  • the in vitro plaque uptake model is a technique in which plaque is grown from thawed form frozen human saliva and treated with various agents to determine the uptake of elemental components into the plaque.
  • a plaque biofilm was grown on glass rods from frozen pooled human saliva and Trypticase Soy Broth (TSB) at 37° over 3 days by dipping glass rods into and out of media in a reciprocating motion. Treatments were 2 minutes of dentifrice slurry in sterile water (1:5). After treatments, biofilms are dried, weighed, digested and analyzed by either ISE (fluoride) or ICP-OES (Ca, Sn, Zn, etc).
  • new glass rods (5 mm ⁇ 90 mm) were polished approximately 25 mm from the un-tapered end on a lathe with silicon carbide paper of 240, 320, 400, and 600 grit used sequentially. After the initial polishing, the rods should be polished with 600 grit paper before each test. After polishing, rods were stored until ready to run test. Enough rods should be polished for a full rack of treatments. A rack can treat 12 compositions with 4 replicates of each composition such that the rack has 48 rods. Saliva was collected daily from a panel of 5-10 people by paraffin stimulation and frozen overnight. Pool saliva carefully (do not pour in wax/mucus) and mix thoroughly before use. Enough saliva should be frozen prior to the study starting to last the entire study. Saliva should be collected from panelists free from disease, who are not on any antibacterial medication or medication that modifies saliva flow, and who brush regularly with Crest Cavity Protection.
  • the rods were removed from storage, rinsed with deionized water to remove any sanding residue, disinfected in 70% ethanol/water solution, and were allowed to dry on a sterile surface. Subsequently, the rods were loaded into a hanging rack of holders that were used to dip the rods continuously into media vials containing growth media. The rod heights were adjusted and each rod was secured in place using a rubber o-ring.
  • 7 mL of growth media 160 g of a solution of 3% TSB (VWR, Radnor, Pa.) with 3% sucrose (VWR, Radnor, Pa.) was mixed with 240 g thawed pooled human saliva.
  • This TSB/sucrose solution should be sterilized by autoclave before combining with the pooled human saliva.
  • Frozen saliva can be thawed in the refrigerator or in a bucket of warm, not hot, water) into media vials.
  • the media vials were arranged under the hanging rods on a rack in an incubation oven.
  • the incubator has been previously modified such that a dipping motor can dip the rods into the media vials submerging 1.5 cm of the rod into the growth media at a frequency of 1 dip per minute without the rods touching the walls of the media vial.
  • the rods were dipped overnight this way.
  • an enriched growth media was prepared (500 g of a solution of 3% TSB and 10% sucrose was mixed with 33 g thawed pooled human saliva. This TSB/sucrose solution should be sterilized by autoclave before combining with the pooled human saliva.).
  • This enriched growth media was pipetted into a new set of media vials (7 mL per vial) and was swapped for the overnight growth media. The rods were dipped throughout the day in this enriched growth media for 5 hours at 37° C. in the incubation oven.
  • a new overnight growth media was prepared (40 g of a solution of 3% TSB was mixed with 360 g pooled human saliva and 0.5 g sucrose), pipetted into a new set of media vials, and swapped for the enriched growth media.
  • the rods were dipped overnight in the same fashion as on the first day.
  • treatment slurries were prepared by homogenizing 4 g of treatment composition with 20 g deionized water and pipetted into treatment vials (7 mL) around such that the rods can be dipped into them. If the slurries were prepared ahead of time, they should be agitated via pipette immediately prior to treatment to ensure good suspension of solid sources of calcium. Two sets of vials were prepared containing 12 mL of deionized water to rinse off the treatments.
  • the rods were dipped into the treatment vials for 2 minutes, rinsed for 10 dips in a first set rinse vials, rinsed for 10 dips in a second set of rinse vials, rinsed for 10 dips in a third set of rinse vials, and returned to the incubator rack.
  • the entire biofilm was treated and rinsed. Once all treatments were complete, the biofilms on the rods were returned to the incubator oven to dry. It is very important that the biofilm on the rods not touch the walls of any of the media, treatment, or rinse vials that would result in the removal of biofilm.
  • the final analysis for calcium occured after the rods were weighed to determine their weight with biofilm, digesting the rods at 90° C. in concentrated nitric acid (BDH, Radnor, Pa., Aristar Plus for trace metal analysis) in a 50 mL conical tube, removing the rods from the digest, cooling and diluting the digest to 50 mL with deionized water, and analyzing the digest for Ca via inductively coupled plasma-optical emission spectroscopy (ICP-OES) or inductively coupled plasma-mass spectrometry (ICP-MS) (Agilent, Santa Clara, Calif.). Rinsed and dried rods were weighed, and the biofilm mass was calculated by subtracting the biofilm-free rod mass from the rod mass with biofilm.
  • ICP-OES inductively coupled plasma-optical emission spectroscopy
  • ICP-MS inductively coupled plasma-mass spectrometry
  • the total calcium mass in the biofilm was determined for each rod from the analysis of the digest and divided by the biofilm mass for that rod to determine the mass-normalized calcium uptake that was then averaged across the replicates.
  • the ratio of the calcium uptake between an experimental treatment and that of Crest Cavity Protection was determined by dividing the mass-normalized calcium uptake for the experimental treatment averaged across the replicates by the mass-normalized calcium uptake for the Crest Cavity Protection treatment averaged across the replicates.
  • the mass-normalized calcium uptake for the Crest Cavity Protection group should be about 0.5-3 micro-g Ca /mg biofilm . If not, the test should be repeated.
  • the mass-normalized calcium uptake for Tom's of Maine Rapid Relief Sensitive should be about 2-3.5 times that of Crest Cavity Protection. If not, the test should be repeated.
  • the HAP dissolution method was designed to test the acid protection of a chosen test dentifrice. After treating hydroxyapatite powder (HAP) with test dentifrice slurries, the HAP is added to an acidic media and the change in pH is an indicator of the degree of surface adsorption. The smaller the pH rise, the better the surface protection.
  • HAP hydroxyapatite powder
  • Dentifrice slurries (1:3 paste:water) were prepared for the experiment. Specifically, 10 g of dentifrice paste was combined with 30 g of deionized water in a 50 mL container with a stir bar. The container was placed on a stir plate to mix until the two components were mixed. The paste slurries were centrifuged at 15,000 rpm for 15 min to isolate their supernatant.
  • HAP hydroxyapatite powder
  • Each treated HAP sample was immediately vortex mixed (DVX-2500 multi-tube vortexer, VWR, Radnor, Pa.) at 2500 rpm for 2 minutes. All samples were then centrifuged at 15,000 rpm for 15 minutes. The liquid phase was decanted out of the centrifuge tube, which left a HAP pellet.
  • the remaining HAP pellet was rinsed three times by adding deionized water, vortex mixing at 2500 rpm for 1 minute, centrifuging at 15,000 rpm for 15 minutes, and the liquid phase was decanted out of the centrifuge tube.
  • the treated HAP pellet was dried in a 55° C. oven overnight.
  • the fluoride-free composition should be made in order to determine its fluoride-free HAP dissolution efficacy ensuring that the pH and counter ion content (Na, Sn, etc.) has been properly controlled.
  • the HAP dissolution efficacy was estimated based on the reported or formulated Sn content of the sample using a previously existing relationship. This relationship is given in FIG. 4 .
  • the method will have been run correctly when the pH change for the water treated control samples is between about 1.3 and 1.5 pH units at 10 minutes. The method should be practiced and repeated until this result is achieved. For guidance, a pH change for a 1100 ppm F as NaF treated control sample should be between about 0.9 and 1.1.
  • the anti-cavity performance of oral care compositions can be substantiated in rats using several methods (Stookey, et al. Adv. Dent. Res. 9(3):198-207, 1995). All of the data presented here use methods disclosed as part of the FDA Method 37 in the anti-caries monograph. The example given here is how our historical data were collected. This method is further described in the following articles: Francis, M D, Arch. Oral Biol. 11:141-1489, 1966; Briner, W W and Francis, M D, Caries Res. 5:180-187, 1971; Donaldson, J D, White, W E, Briner, W W, and Cooley, W E, J. Dent. Res. 53:648-652, 1974.
  • Wistar rats were obtained from Harlan Industries, Inc., Cumberland, Ind. They were shipped via truck and arrived on Day 0 at 22-23 days of age. Animals were received in twenty litters of ten randomly sexed animals per litter, thus providing the 200 animals used in a standard rat caries study. One animal from each litter was then randomly allocated to one of the treatment groups and placed in a numbered stainless-steel, wire-bottom cate (litter mates occupy the same position in each group; e.g., all animals form litter #1 were allocated to the first cage of each treatment group). Animals were then weighed in and the weight was recorded in the lab book. Animals were fed cariogenic diet #469 ad libitum and deionized water ad libitum.
  • the swab is dipped into a slurry prepared with toothpaste diluted 1:1 with deionized water. This dilution was mixed on a stir-plate for five minutes prior to treatment application.
  • the dipped swab was brushed against the maxillary molars with a front-to-back stroke repeated six times.
  • the swab was dipped into the treatment slurry and then rotated toward the cheek, thereby moving around the tongue to reach the mandible molars. Again, six rotations per mandible were required.
  • Treatment was applied twice daily, beginning the Day 1 after arrival, through Day 3. (Day 4, normally a Saturday, and Day 5, normally a Sunday were not treatment days.) Treatment resumed on Day 6 through Day 10 with the weekend off (Days 11 and 12), and again resumed on Day 13 through Day 17 with Days 18 and 19 off. The following week the animals were treated on Day 20 and Day 21, and a final body weight was obtained.
  • the aluminum baking pans containing the heads were autoclaved at approximately 120° C. and 10 lbs. pressure for 35 minutes, after which the steam was turned off and the pans were allowed to stand for another 15 minutes before the heads were removed.
  • the bones containing both the upper and lower molars for each rat could easily be lifted from the surrounding tissue and placed into the animal's pre-number plastic vial for future identification. These vials were left open for 24-36 hours to dry at room temperature and were then closed until they were to be sectioned.
  • each quadrant was hemi-sectioned longitudinally, and each section was permanently mounted on the microscope slide.
  • Each quadrant occupied the same position on the slide as in the animal's mouth (e.g., the right upper quadrant was mounted on the right upper corner of the slide).
  • a percent reduction is calculated for each treatment group. This is done by subtracting the score of the test group from that of the water or placebo control group and then dividing by the water or placebo control group score. This number is expressed as a percent by multiplying by 100. Further statistical analysis was performed to determine significant differences among the groups if they existed. A standard analysis of variance was used. Treatments were ranked by a Newman-Keuls analysis. All historical method scores have been converted to Modern Method equivalent scores as part of establishing the rat caries meta-analysis.
  • test design used here is similar to those found in the FDA Method #37 of the Fluoride Anti-Caries OTC Monograph. The major variations are the diet used (MIT 200 rather than #469), the caries score method (Keyes method rather than HMA), and treatment frequency. Experimental procedures were conducted according to the FDA regulations Part 58.
  • the animals were weanling mixed-sex Sprague Dawley rats; weighing 29-53 grams. Due to the shipping schedule of the supplier, the dams were received with their entire birth litter. The litters were received when the pups were 6 days of age and litter size was reduced at 8 days of age to ten (10) pups per litter. Twenty-five (25) litters were purchased. The five extra litters were to allow for any mortality prior to stratification. Any unused animals were euthanized after the study stratification.
  • the litters were maintained in large solid-bottom (box-type) cages with dams until the pups were weaned at 18 days of age. Starting at 9 days of pup age, the dams were rotated daily among the litters until the pups were weaned at 18 days of age. The pups were maintained in the box cages until 21 days of age. At that time, the pups were stratified and housed in pairs in suspended wire-bottomed cages that had been cleaned and sanitized prior to usage. The change in caging was required to prevent artificially increasing the caries rate due to direct contact bedding.
  • the cages were arranged so that all animals of the individual groups were together and the cages were labeled with group designation and treatment (treatment code) that the animals received.
  • dams and litters were provided rodent lab diet until the pups were 8 days of age. On day 8 (pup age) dams and litters were provided Diet MIT 305. Pups were provided Diet MIT 200 ad libitum at day 18 (pup age) and throughout the test period. All animals were provided with deionized water ad libitum.
  • Box caging was changed at day 13 and again at day 18 of pup age. Following administration of the inoculum, box cages and the bedding were decontaminated by autoclaving prior to sanitizing. Cage boards were changed three times a week at the time when fresh food and water were given (Monday, Wednesday and Friday). Clean and sanitized water bottles and food jars were provided weekly. Suspended caging and banks were sanitized bi-weekly. The animals were observed daily by a staff member and weekly by the attending veterinarian for any signs of health problems. The animals were housed in an AAALAC-accredited facility. Room temperature was maintained at 72° F. ( ⁇ 6° F.) with 10-15 air changes per hour and a 12-hour light cycle.
  • the treatment phase began at day 22 of pup age. Each treatment had a labeled plastic beaker that was designated for that treatment only. Fresh materials (i.e., obtained from the stock supply) were used for each treatment.
  • the dentifrices were mixed in a 1:1 ratio (by weight) with deionized water. Specifically, 10 grams of dentifrice was weighed into a 30 ml beaker; 10 grams of deionized water was then added to the dentifrice. The mixture was then stirred by hand (30 seconds) with a clean micro spatula for the purpose of creating a smooth mixture.
  • the beaker containing the slurry and a small magnetic stirring bar was placed on a magnetic stirrer, which was set at the lowest speed and allowed to stir for four (4) minutes prior to treatment. The slurry was prepared immediately prior to each treatment.
  • a cotton-tipped applicator was dipped into the slurry (for 2 seconds) and was applied to one-half of the rat's mouth in such a way that the sides of the applicator came into contact with both the mandibular and maxillary molars on one side of the mouth.
  • the treatment was accomplished by using a rolling motion of the sides of the applicator over the mandibular and maxillary molar teeth for 15 seconds.
  • the applicator was dipped into the slurry for the second time (again, for 2 seconds) and the other side of the rat's mouth similarly treated for 15 seconds. A new applicator was used for each animal.
  • Treatments were administered twice daily for five days with a single daily treatment on weekends. The first treatment each day began at approximately the same time every day, and the second treatment did begin no earlier than six hours after the first treatment. Singular treatments were given at a 24-hour interval on weekends. Treatment materials were stored at room temperature. All treatment products were returned to sponsor at study completion.
  • the experimental duration of the rat caries studies is three weeks. Immediately prior to termination, all animals were observed for any visual signs of ill health or pathology, individually weighed and an oral swabbing taken to confirm S. sobrinus implantation. The animals were euthanized by carbon dioxide inhalation. Code numbers were assigned to each animal and the heads were then removed, placed in individual jars along with the code number, and cooked under pressure (10 PSI for 12 minutes). The hemijaws were then removed and freed of all soft tissue.
  • the cleaned hemijaws (four quadrants) were put into plastic vials with the code numbers taped to the vial.
  • a murexide solution (0.3 g murexide; 300 ml DI H20 and 700 ml of ethanol) was added to each vial and the jaws were allowed to stain overnight. The jaws were then rinsed and allowed to air dry.
  • the hemijaws were microscopically examined for smooth surface caries, sectioned, and then microscopically examined for sulcal and interproximal caries using the Keyes Method.
  • the scoring method is detailed in Navia, J N, Animal Models in Dental Research, pp 287-290, 1977; and Keyes, P H, J. Dent. Res. 37:1088-1099, 1958. All analyses were performed using SAS statistical software, version 9.4.
  • the oral care compositions of TABLE 1A were prepared by combining one or more humectants, water, sweetener(s), tin ion source, sodium gluconate, and/or flavor(s) to create a liquid mixture.
  • the liquid mixture was homogenized at 25° C. for 2 minutes.
  • sodium hydroxide (50% solution) was added to the liquid mixture and the liquid mixture was homogenized at 25° C. for 2 minutes.
  • a separate powder mixture was prepared by combining a portion of the calcium ion source and any thickening agents, such as xanthan gum and/or sodium carboxymethylcellulose. The powder mixture was then combined with the liquid mixture.
  • the surfactant such as sodium lauryl sulfate, was added to the mixture.
  • the contents were homogenized at 25° C. for 2 minutes.
  • the hops extract was then combined with the mixture and homogenized at 25° C. for 2 minutes.
  • the remaining portion of the calcium ion source and the buffering agent were combined with the mixture and homogenized at 25° C. for 2 minutes.
  • the commercial oral care compositions were combined with hops beta acid by weighing out a portion of commercial oral care composition and mixing in the appropriate amount of hops beta extract.
  • the combined oral care composition was homogenized at 25° C. for at least 2 minutes.
  • Ex. 1a, 1b, 1c, and 1d were prepared in accordance with the Experimental Methods, described above.
  • the Hops Beta Acids were supplied by Hopsteiner® as an extract from Humulus lupulus.
  • the Hopsteiner® extract was approximately 45%, by weight of the extract, of hops beta acids and less than 1%, by weight of the extract, of hops alpha acids.
  • Ex. 1a and 1c have 13% water while Ex. 1b and 1d do not have any separately added water.
  • Ex. 1a and Ex. 1b are free from fluoride while Ex. 1c and 1d have sodium monofluorophosphate.
  • TABLE 1B describes the hops beta acid extract provided by Hopsteiner®. Since the hops beta acids are provided as an extract, there can be some variability in the amounts of certain ingredients. However, the extract comprises approximately 45%, by weight of the extract, of the hops beta acids and approximately 0.4%, by weight of the extract, of hops alpha acids. This is dramatically different to previous hops extracts which typically have more hops alpha acids than hops beta acids. Other minor ingredients may be present in the Hops Beta Acid extract.
  • HAP Dissolution Reduction Vector % Reduction % Reduction Treatment Leg v Control Predicted HAP 1000 ppm F as SnF 2 3.4 9.0 13 Dentifrice + 9000 ppm Sn 1000 ppm F as SnF 2 — — 0 Dentifrice 1100 ppm F as SnF 2 19 10 14 Dentifrice + 10,000 ppm Sn 1100 ppm F as SnF 2 14 10 14 Dentifrice + 10,000 ppm Sn 1100 ppm F as SnF 2 12 12 17 Dentifrice + 12,500 ppm Sn 1100 ppm F as NaF — — 0 Dentifrice
  • TABLE 3 shows the variation in anticaries efficacy with respect to soluble fluoride content as determined by the ADA method.
  • a 650 ppm fluoride as sodium fluoride was estimated to effect a reduction in caries of about 29%, or about 25%, or about 30%, with respect to the placebo or water control in rat caries experiments.
  • the table indicates the expected caries reduction in the rat model for the transition from subtherapeutic to therapeutic levels of fluoride delivered as sodium fluoride.
  • TABLE 4 shows the variation in anticaries efficacy with respect to Sn-Free antibacterial activity as measured by the Sn-Free iPGRM. Since the iPGRM measures reduction in antibacterial efficacy through changes in the pH, non-antibacterial agents that modify pH, such as sodium bicarbonate, can be corrected for when determining the efficacy of the antibacterial agent. This can be done using placebo controls as necessary. The contribution of Sn was measured through the solubility reduction and is excluded from this test. The iPGRM dose response of chlorhexidine is shown in FIG. 2 .
  • TABLE 5 shows the variation in anticaries efficacy with respect to calcium co-ion effect as measured by the iPUM.
  • This method measures the total calcium uptake of both soluble and insoluble sources. If an insoluble source was used, calcium sources were preferred that were substantially more soluble than hydroxyapatite so that they will dissolve preferentially when exposed to plaque acids. For example, dicalcium phosphate or calcium carbonate dissolve readily on exposure to acid while calcium pyrophosphate is a poor source of calcium for the purposes here. Calcium pyrophosphate does not readily dissolve on exposure to acid and is a poor source of calcium for the purposes of protecting teeth from plaque acids through a co-ion effect. Nevertheless, insoluble sources have the advantage of increased residence time in the plaque and can, therefore, provide a bloom of calcium to correspond temporally to the generation of plaque acid.
  • the iPUM dose response of calcium-containing compositions is shown in FIG. 3 .
  • TABLE 6 shows the variation in anticaries efficacy with respect to the F-Free reduction in HAP solubility as measured by F-free HAP.
  • the contribution of the fluoride co-ion effect is measured through the ADA method and is excluded from this test.
  • An example of the F-free HAP response for different levels of Sn in Sn/silica toothpastes is given in FIG. 4 .
  • the threshold can be defined for which combinations of subtherapeutic compositions result in a therapeutic composition.
  • this transition can be defined for those compositions providing a reduction in rat caries of approximately 29% with a statistically significant reduction in caries with respect to the water or F-placebo/silica toothpaste negative control.
  • performance can be substantiated using an actual rat caries performance test.
  • Rat caries is the preferred animal model for human caries and is included in the US Anticaries Monograph (21 CFR part 355) to ensure the efficacy of fluoride-containing products. It is additionally sensitive to non-fluoride anticaries mechanisms and compositions.
  • animal models for caries are generally considered interchangeable as long as they have been properly developed.
  • the present invention is directed to a combination of subtherapeutic compositions can result in therapeutic composition when tested in total.
  • the examples can allow for the setting of performance thresholds for the subtherapeutic to therapeutic transition in each mechanism as defined by the specified performance test. However, those results, alone, might not anticipate the combined performance of the compositions in a rat caries experiment. Thus, the thresholds for the transition from a subtherapeutic to a therapeutic dose for each mechanism were modeled with historical rat caries data. The analysis gave a model from which can predict reductions in rat caries for combinations of subtherapeutic compositions as described herein. In combination, the examples, performance thresholds, and mathematical model can help define the scope of the present invention.
  • the prediction formula is reproduced below for the % reduction in rat caries with respect to water or a silica-based-abrasive, placebo-toothpaste negative control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
US17/037,780 2019-09-30 2020-09-30 Oral Care Compositions With Anticaries Activity Pending US20210093528A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/037,780 US20210093528A1 (en) 2019-09-30 2020-09-30 Oral Care Compositions With Anticaries Activity

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962907735P 2019-09-30 2019-09-30
US201962907733P 2019-09-30 2019-09-30
US201962907736P 2019-09-30 2019-09-30
US201962943940P 2019-12-05 2019-12-05
US202062972109P 2020-02-10 2020-02-10
US202062972111P 2020-02-10 2020-02-10
US202062985451P 2020-03-05 2020-03-05
US202062994893P 2020-03-26 2020-03-26
US17/037,780 US20210093528A1 (en) 2019-09-30 2020-09-30 Oral Care Compositions With Anticaries Activity

Publications (1)

Publication Number Publication Date
US20210093528A1 true US20210093528A1 (en) 2021-04-01

Family

ID=72896185

Family Applications (7)

Application Number Title Priority Date Filing Date
US17/037,776 Active US11690792B2 (en) 2019-09-30 2020-09-30 Oral care compositions comprising hops beta acids and metal ions
US17/037,773 Pending US20210093549A1 (en) 2019-09-30 2020-09-30 Fluoride-Free Anticavity Oral Care Compositions
US17/037,789 Pending US20210093551A1 (en) 2019-09-30 2020-09-30 Methods Of Use Of Oral Care Compositions Comprising Hops
US17/037,766 Active US11696881B2 (en) 2019-09-30 2020-09-30 Oral care compositions comprising hops beta acids and fluoride ions
US17/037,780 Pending US20210093528A1 (en) 2019-09-30 2020-09-30 Oral Care Compositions With Anticaries Activity
US18/322,979 Pending US20230310287A1 (en) 2019-09-30 2023-05-24 Oral Care Compositions Comprising Hops Beta Acids And Fluoride Ions
US18/322,652 Pending US20230293401A1 (en) 2019-09-30 2023-05-24 Oral Care Compositions Comprising Hops Beta Acids And Metal Ions

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US17/037,776 Active US11690792B2 (en) 2019-09-30 2020-09-30 Oral care compositions comprising hops beta acids and metal ions
US17/037,773 Pending US20210093549A1 (en) 2019-09-30 2020-09-30 Fluoride-Free Anticavity Oral Care Compositions
US17/037,789 Pending US20210093551A1 (en) 2019-09-30 2020-09-30 Methods Of Use Of Oral Care Compositions Comprising Hops
US17/037,766 Active US11696881B2 (en) 2019-09-30 2020-09-30 Oral care compositions comprising hops beta acids and fluoride ions

Family Applications After (2)

Application Number Title Priority Date Filing Date
US18/322,979 Pending US20230310287A1 (en) 2019-09-30 2023-05-24 Oral Care Compositions Comprising Hops Beta Acids And Fluoride Ions
US18/322,652 Pending US20230293401A1 (en) 2019-09-30 2023-05-24 Oral Care Compositions Comprising Hops Beta Acids And Metal Ions

Country Status (9)

Country Link
US (7) US11690792B2 (fr)
EP (4) EP4037781A1 (fr)
JP (4) JP7428790B2 (fr)
CN (4) CN114449996A (fr)
AU (6) AU2020360256B2 (fr)
BR (4) BR112022005883A2 (fr)
CA (4) CA3155923A1 (fr)
MX (4) MX2022003753A (fr)
WO (4) WO2021067996A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133368A1 (fr) 2022-01-04 2023-07-13 The Procter & Gamble Company Systèmes et procédés d'imagerie numérique basés sur des soins buccodentaires pour évaluer un produit de soins buccodentaires
US11918681B2 (en) 2019-09-30 2024-03-05 The Procter & Gamble Company Oral care compositions comprising hops beta acid and amino acid

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022067141A1 (fr) * 2020-09-28 2022-03-31 The Procter & Gamble Company Compositions aqueuses comprenant un complexe houblon-métal
WO2022245567A1 (fr) * 2021-05-20 2022-11-24 Smile Makers, Llc Compositions d'hygiène buccale et procédés d'utilisation

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL179202B (nl) 1952-06-17 Sumitomo Chemical Co Werkwijze voor het bereiden van alkynyl-cyclopropaancarboxylaten, en ten minste een dergelijke verbinding bevattende insecticide preparaten.
AU411533B2 (en) 1965-03-24 1971-03-08 The Colonial Sugar Refining Company Limited Compositions of matter containing complex cariostatic agents
GB1115370A (en) 1961-07-10 1968-05-29 Colonial Sugar Refining Co Compositions of matter containing complex cariostatic agents
DE1492185A1 (de) 1964-10-20 1969-12-04 Stralfors Carl Emanuel Allan Desinfektionsmittel zur Verhinderung von Karies
US3956479A (en) 1966-09-13 1976-05-11 Colgate-Palmolive Company Pharmaceutical composition containing novel quaternary ammonium compounds
US4166073A (en) 1968-03-27 1979-08-28 Colgate Palmolive Company Unsymmetrical oligoquaternary ammonium compounds
US3914404A (en) 1969-01-10 1975-10-21 Dow Chemical Co Dentifrices and method for reducing enamel solubility
US3985869A (en) 1969-06-07 1976-10-12 Dainippon Pharmaceutical Co., Ltd. Dental caries-inducing microorganism cells lytic enzyme
US4048299A (en) 1969-09-05 1977-09-13 William Wrigley, Jr. Co. Anticaries confectionaries and oral health products
US3624120A (en) 1969-12-22 1971-11-30 Procter & Gamble Quaternary ammonium salts of cyclic siloxane polymers
US3639570A (en) 1970-11-16 1972-02-01 Colgate Palmolive Co Oral hygiene with aminopolyureylene resin
AU461954B2 (en) 1970-11-16 1975-06-12 Colgate-Palmolive Company Cosmetic compositions
US3932603A (en) 1971-05-28 1976-01-13 General Foods Corporation Oral preparations for reducing the incidence of dental caries
US3925556A (en) 1971-09-30 1975-12-09 Colgate Palmolive Co Anti microbial compositions containing unsymmetrical oligoquaternary ammonium compounds
US3953605A (en) 1972-04-10 1976-04-27 Colgate-Palmolive Company Antimicrobial quaternary ammonium compounds compositions
US4022880A (en) 1973-09-26 1977-05-10 Lever Brothers Company Anticalculus composition
CH598821A5 (fr) 1974-05-31 1978-05-12 Gaba Ag
GB1548377A (en) 1975-04-22 1979-07-11 Ferrosan Ab Piperidine derivatives and their use in compositions for the treatment of teeth and the oral cavity
GB1547874A (en) 1976-05-19 1979-06-27 Unilever Ltd Dentifrices
ZA773318B (en) 1976-06-18 1978-04-26 I Kleinberg Means and method for improving natural defenses against caries
US4042680A (en) 1976-08-02 1977-08-16 Indiana University Foundation Anticariogenic maloaluminate complexes
US4108981A (en) 1976-08-02 1978-08-22 Indiana University Foundation Alkaline oral compositions comprising aluminum and a carboxylic acid
US4416867A (en) 1979-06-20 1983-11-22 Lever Brothers Company Oral compositions
JPS57165312A (en) 1981-04-03 1982-10-12 Handai Biseibutsubiyou Kenkyukai Production of oral composition
US4435381A (en) 1983-07-18 1984-03-06 The Dow Chemical Company Thiouronium phosphonates for use in dental treatments
US4618489A (en) 1983-09-02 1986-10-21 Research Foundation Of The State University Of New York Dental compositions and method of use therefor
US4737359A (en) 1985-04-18 1988-04-12 Colgate-Palmolive Company Control of dental plaque and caries using emulsan
US5064640A (en) 1986-12-02 1991-11-12 Purdue Research Foundation Anticariogenic compositions
US4976954A (en) 1986-12-02 1990-12-11 Purdue Research Foundation Anticariogenic compositions
US5531982A (en) 1987-01-30 1996-07-02 Colgate Palmolive Company Antimicrobial oral composition
JP2594787B2 (ja) 1987-02-27 1997-03-26 大洋香料株式会社 う蝕予防剤
EP0311260B1 (fr) 1987-09-14 1994-12-28 The Procter & Gamble Company Composition buccales
AU648040B2 (en) 1989-11-15 1994-04-14 Gillette Canada Inc. Stabilized stannous fluoride compositions for oral care
US5180577A (en) 1990-10-09 1993-01-19 Colgate-Palmolive Stabilized bis biguanide/anionic active ingredient compositions
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5281410A (en) 1991-10-23 1994-01-25 The Proctor & Gamble Company Methods of reducing plaque and gingivitis with reduced staining
US5370863A (en) * 1992-12-16 1994-12-06 Miller Brewing Company Oral care compositions containing hop acids and method
DE69328903T2 (de) 1992-12-16 2000-12-07 Colgate Palmolive Co Gegen zahnbelag, gingivitis und karies wirkende orale zusammensetzung
US6136298A (en) * 1994-07-14 2000-10-24 Colgate-Palmolive Company Process for inhibiting S. mutans and caries
US5534243A (en) 1994-09-26 1996-07-09 The Procter & Gamble Company Aqueous oral compositions
EP1203575B1 (fr) 1995-05-03 2010-09-01 Unilever N.V. Dentifrice sous forme de gel optiquement clair
US5762911A (en) 1996-03-05 1998-06-09 The Research Foundation Of State University Of New York Anti-caries oral compositions
JP3440694B2 (ja) 1996-05-16 2003-08-25 ライオン株式会社 口腔用組成物
US5961958A (en) 1996-07-16 1999-10-05 Four Star Partners Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth
KR19980075132A (ko) 1997-03-28 1998-11-05 민병무 중간사슬지방산(medium-chain fatty acids)을 유효성분으로 하는 치아우식증 및 치주질환 치료제용 의약조성물
US6241974B1 (en) 1997-04-22 2001-06-05 The Procter & Gamble Company Dentifrice compositions containing β-phase calcium pyrophosphate an anticalculus agent, and fluoride
AU8747498A (en) 1997-08-22 1999-03-16 Nippon Shinyaku Co. Ltd. Food-preservative composition
DK176196B1 (da) 1997-10-07 2007-01-08 Ejvind Jersie Pedersen Mundhygejnepræparat til behandling af halitosis samt anvendelse af et chelat omfattende en metaliondel og en aminosyredel som en komponent i præparatet
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
JP3719874B2 (ja) 1998-04-24 2005-11-24 サンスター株式会社 口腔用組成物
CA2334344C (fr) 1998-06-09 2005-08-16 William J. Embro Procede et composition pour le traitement d'irritations et d'infections epidermiques
US6165447A (en) 1999-06-15 2000-12-26 Colgate-Palmolive Company Synergistic antibacterial combination
US6475537B1 (en) * 2000-07-27 2002-11-05 Rhodia Inc. Hops acid antibacterial compositions
US6129907A (en) 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
JP2001258502A (ja) 1999-09-07 2001-09-25 Takeda Chem Ind Ltd 甘味料組成物、甘味付与方法およびその利用
GB2355008A (en) 1999-10-05 2001-04-11 Procter & Gamble Foam matrix coating material
US6685920B2 (en) * 1999-11-12 2004-02-03 The Procter & Gamble Company Method of protecting teeth against erosion
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
US20030003059A1 (en) 2001-04-03 2003-01-02 Frederic Dana Dentifrice compositions
US20030003069A1 (en) 2001-04-04 2003-01-02 Carson John C. Multiple phase foaming personal cleansing products
US20040057908A1 (en) 2001-12-13 2004-03-25 Bowen William H. Oral compositions and use thereof
US20030157145A1 (en) 2002-01-24 2003-08-21 Kalili Tom K. Fluoridated products
CN100387255C (zh) 2002-05-17 2008-05-14 S·S·斯坦纳公司 啤酒花酸作为抗微生物剂的改良应用
AU2003211673A1 (en) 2003-02-25 2004-10-11 Jason Medical Group (Far East) Limited A PREPARATION METHOD OF IgY FOR PREVENTING AND CURE MOUTH DISEASE AND THE TOOTHPASTE BASE ON THE IgY
US20040175480A1 (en) 2003-03-03 2004-09-09 Kraft Foods Holdings, Inc. Hop beta acid compositions for use in food products
US20060216248A1 (en) 2003-04-30 2006-09-28 Asahi Breweries, Ltd. Material for inhibiting enamel decalcification
US8524198B2 (en) 2003-06-20 2013-09-03 Donald W. Bailey Xylitol dental maintenance system
ITMI20032287A1 (it) 2003-11-24 2005-05-25 Indena Spa Composizioni per il trattamento delle affezioni del cavo orale e delle prime vie respiratorie
KR20070097581A (ko) 2004-03-26 2007-10-04 아사히비루 가부시키가이샤 치근막 보호제
US20090202453A1 (en) 2004-08-03 2009-08-13 Hindustan Lever Limited Oral Composition
JP4347161B2 (ja) 2004-08-20 2009-10-21 キリンフードテック株式会社 ホップ抽出物含有組成物
DE102004043945A1 (de) 2004-09-11 2006-03-30 Henkel Kgaa Mund-, Zahn- und Zahnprotesenpflegemittel enthaltend die Plaquebildung inhibierende Substanzen
WO2006040189A1 (fr) 2004-10-15 2006-04-20 Rhodia Chimie Composition comprenant un agent benefique a base d'extrait de houblon
US8173144B2 (en) 2004-11-04 2012-05-08 L'oreal Administration of urea compounds for combating signs of cutaneous aging
US8900644B2 (en) 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
US20060287554A1 (en) 2005-06-21 2006-12-21 Madsen Kevin K Process for producing inorganic salts of hop acids
GB0514943D0 (en) 2005-07-20 2005-08-24 Botan Ltd Oral care compositions
US20070116829A1 (en) 2005-11-23 2007-05-24 The Coca-Cola Company Pharmaceutical Composition with High-Potency Sweetener
KR101402637B1 (ko) 2006-03-22 2014-06-03 다카사고 고료 고교 가부시키가이샤 소취제 조성물
US7371389B2 (en) 2006-04-14 2008-05-13 Arbonne International, Llc Methods and products for enhancing energy and nutrition in human beings
US8071136B2 (en) 2006-04-21 2011-12-06 Bioactives, Inc. Water-soluble pharmaceutical compositions of hops resins
CA2663913A1 (fr) 2006-10-02 2008-04-10 The Procter & Gamble Company Compositions d'hygiene buccale stanneuses
WO2008065875A1 (fr) 2006-11-30 2008-06-05 Sapporo Breweries Limited Agent de rafraîchissement de la bouche et boisson et aliment le contenant
JP5067529B2 (ja) 2006-12-13 2012-11-07 ライオン株式会社 口腔用組成物
US20090186090A1 (en) 2007-04-30 2009-07-23 Colgate-Palmolive Oral Care Composition to Reduce or Eliminate Dental Sensitivity
AU2009212335B2 (en) 2008-02-08 2011-12-01 Colgate-Palmolive Company Compositions comprising basic amino acid and soluble carbonate salt
TWI458468B (zh) 2008-02-08 2014-11-01 Colgate Palmolive Co 牙齒擦拭件
JP6034549B2 (ja) 2008-02-08 2016-11-30 コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ 口腔ケア製品ならびにその使用および製造の方法
US9918918B2 (en) 2008-02-08 2018-03-20 Colgate-Palmolive Company Compositions for tooth-whitening comprising a bleaching agent and a basic amino acid, and methods and devices for application thereof
PE20121701A1 (es) 2008-02-08 2012-12-17 Colgate Palmolive Co Producto de cuidado bucal y fabricacion del mismo
RU2503442C2 (ru) 2008-02-08 2014-01-10 Колгейт-Палмолив Компани Продукт для ухода за полостью рта и способы его применения и изготовления
MX2010004647A (es) 2008-02-08 2010-06-07 Colgate Palmolive Co Producto para cuidado oral y metodos de uso del mismo.
TWI396554B (zh) 2009-05-26 2013-05-21 Colgate Palmolive Co 增進可溶性鋅的量之口腔保健調配物
EP2454272B1 (fr) 2009-07-16 2017-08-23 IASON GmbH Analogues de la neurotensine pour le ciblage par radio-isotopes dans des tumeurs sensibles au récepteur de la neurotensine
JP2011063556A (ja) 2009-09-18 2011-03-31 Gc Corp 口腔内細菌の共凝集阻害剤及びそれを配合した口腔用組成物
MX347064B (es) * 2009-10-29 2017-04-11 Colgate-Palmolive Company * Dentrifico que comprende fluoruro estañoso, citrato de zinc y bajos niveles de agua.
JP2013512905A (ja) * 2009-12-04 2013-04-18 コルゲート・パーモリブ・カンパニー ジンギベル・オフィキナレの抽出物を含有する口腔用組成物および関連する方法
RU2012127779A (ru) 2009-12-04 2014-01-20 Колгейт-Палмолив Компани КОМПОЗИЦИЯ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА, СОДЕРЖАЩАЯ ЭКСТРАКТЫ ИЗ Garcinia mangostana L., И СВЯЗАННЫЕ С НЕЙ СПОСОБЫ
JP5852007B2 (ja) 2009-12-18 2016-02-03 コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ 抗微生物剤の増進剤としてのカルコン類
EP2552382B1 (fr) 2010-03-31 2015-09-09 Colgate-Palmolive Company Composition de soins bucco-dentaires
KR101722490B1 (ko) 2010-06-04 2017-04-04 (주)아모레퍼시픽 잇몸질환 예방에 효과적인 폴리감마글루탐산 함유 구강용 조성물
CN103153267B (zh) 2010-08-18 2015-07-22 高露洁-棕榄公司 口腔护理产品及其使用和制备方法
WO2012044785A2 (fr) 2010-10-01 2012-04-05 The Procter & Gamble Company Compositions pour soins bucco-dentaires à saveur sucrée améliorée
US9119879B2 (en) 2010-12-07 2015-09-01 Colgate-Palmolive Company Oral care compositions comprising a quinone and a further antimicrobial agent
CN103260591B (zh) 2010-12-21 2016-10-26 高露洁-棕榄公司 金属盐组合物
WO2013034421A2 (fr) 2011-09-08 2013-03-14 Unilever N.V. Dentifrice de reminéralisation dentaire
US20130344120A1 (en) 2012-06-21 2013-12-26 Douglas Craig Scott Mouth Rinse Emulsions
EP2925285B1 (fr) 2012-12-03 2018-08-08 GABA International Holding GmbH Composition d'hygiène buccale
EP2928440B2 (fr) 2012-12-05 2019-12-18 Colgate-Palmolive Company Compositions de soin buccal à teneur en zinc stables en fluorure
AU2012396297B2 (en) 2012-12-06 2015-08-20 Colgate-Palmolive Company Surfactant systems for zinc containing compositions
AU2012397267B2 (en) 2012-12-19 2015-10-08 Colgate-Palmolive Company Oral care compositions comprising zinc amino acid halides
US9744108B2 (en) 2013-02-28 2017-08-29 University Of Tennessee Research Foundation Methods and compositions for preventing and treating tooth erosion
WO2014169082A1 (fr) 2013-04-10 2014-10-16 The Procter & Gamble Company Compositions de soins orales contenant des particules de polyorganosilsesquioxane
US20160324738A1 (en) * 2013-06-10 2016-11-10 The Procter & Gamble Company Oral Compositions Containing Stannous
WO2015084321A1 (fr) 2013-12-03 2015-06-11 Colgate-Palmolive Company Compositions de soins buccaux
WO2015131002A1 (fr) 2014-02-27 2015-09-03 The Procter & Gamble Company Compositions de soins bucco-dentaires dont l'amertume perçue est réduite
CN106470662A (zh) 2014-05-07 2017-03-01 宝洁公司 口腔护理组合物
WO2015171837A1 (fr) 2014-05-09 2015-11-12 The Procter & Gamble Company Compositions orales contenant du zinc
WO2015171836A1 (fr) * 2014-05-09 2015-11-12 The Procter & Gamble Company Compositions buccales contenant des composés stanneux
RU2699370C2 (ru) 2014-12-26 2019-09-05 Колгейт-Палмолив Компани Композиции в виде средства для чистки зубов с низким содержанием воды
BR112017012804B1 (pt) 2014-12-26 2020-11-17 Colgate-Palmolive Company composição para higiene bucal e uso de um aminoácido básico ou sal do mesmo, uma fonte de zinco e um preservativo na preparação da referida composição
WO2016130985A1 (fr) 2015-02-13 2016-08-18 The Trustees Of The University Of Pennsylvania Nanoparticules d'oxyde de fer et leurs procédés d'utilisation
US20180021234A1 (en) 2015-07-01 2018-01-25 Colgate-Palmolive Company Oral Care Compositions and Methods of Use
CN106075545A (zh) 2016-06-15 2016-11-09 湖州科达化工燃料有限公司 一种具有抗菌止血功效的软组织用粘合剂
CA2996319C (fr) 2016-06-24 2020-09-15 Colgate-Palmolive Company Composition de soins buccaux a haute teneur en eau comprenant du zinc etdu sel d'etain
CN106389138A (zh) 2016-08-24 2017-02-15 宁波枫叶杰科生物技术有限公司 一种含有草本精华提取物的漱口水
CN106309215A (zh) 2016-08-24 2017-01-11 宁波枫叶杰科生物技术有限公司 一种含有草本精华提取物的牙膏
CN106309629A (zh) 2016-08-24 2017-01-11 宁波枫叶杰科生物技术有限公司 一种草本精华提取物及其制备方法
US10280444B2 (en) 2016-09-09 2019-05-07 The Procter & Gamble Company Method of quantitating sorption of stannous by microbial cells of a biofilm
US20180072944A1 (en) 2016-09-15 2018-03-15 The Procter & Gamble Company Stannous Fluorescent Probe
US10058493B2 (en) 2016-12-21 2018-08-28 Colgate-Palmolive Company Oral care compositions and methods of use
CN106937921A (zh) 2017-03-13 2017-07-11 南通蛇类治疗研究所 酵素酶牙膏
CN107485599A (zh) 2017-09-02 2017-12-19 西南大学 安全可食用不含氟儿童牙膏
CN107468587B (zh) 2017-09-14 2020-09-22 好维股份有限公司 一种包含稳定多酚的口腔护理组合物
MX2020006002A (es) 2017-12-13 2022-05-27 Colgate Palmolive Co Composiciones para el cuidado bucal y metodos para aumentar su estabilidad.
CN117618259A (zh) 2018-03-29 2024-03-01 宝洁公司 用于促进牙龈健康的口腔护理组合物
AU2018415261B2 (en) 2018-03-29 2021-11-04 The Procter & Gamble Company Oral care compositions for promoting gum health
JP7058341B2 (ja) 2018-03-29 2022-04-21 ザ プロクター アンド ギャンブル カンパニー 歯肉健康を促進するための口腔ケア組成物
MX2020009174A (es) 2018-03-29 2021-07-29 Procter & Gamble Composiciones para el cuidado bucal para promover la salud de las encías.
CN108938544A (zh) 2018-09-21 2018-12-07 南通蛇类治疗研究所 酵素酶天然牙膏
JP2019052186A (ja) * 2018-12-26 2019-04-04 日新製糖株式会社 口腔用組成物
EP3918657A1 (fr) 2019-01-30 2021-12-08 Solvay Specialty Polymers Italy S.p.A. Électrolyte composite solide
WO2021062607A1 (fr) 2019-09-30 2021-04-08 The Procter & Gamble Company Compositions de soin buccal comprenant un bêta acide et un acide aminé hops

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918681B2 (en) 2019-09-30 2024-03-05 The Procter & Gamble Company Oral care compositions comprising hops beta acid and amino acid
WO2023133368A1 (fr) 2022-01-04 2023-07-13 The Procter & Gamble Company Systèmes et procédés d'imagerie numérique basés sur des soins buccodentaires pour évaluer un produit de soins buccodentaires

Also Published As

Publication number Publication date
CA3155923A1 (fr) 2021-04-08
JP7377962B2 (ja) 2023-11-10
JP2022549867A (ja) 2022-11-29
MX2022003753A (es) 2022-05-02
CN114466651A (zh) 2022-05-10
EP4037777A1 (fr) 2022-08-10
US20210093550A1 (en) 2021-04-01
AU2020360256A1 (en) 2022-03-10
BR112022004374A2 (pt) 2022-06-07
US11690792B2 (en) 2023-07-04
JP2022549677A (ja) 2022-11-28
AU2024201749A1 (en) 2024-04-04
US20230310287A1 (en) 2023-10-05
AU2020357202B2 (en) 2024-03-28
AU2020357203A1 (en) 2022-03-10
JP2022549339A (ja) 2022-11-24
MX2022003756A (es) 2022-05-03
EP4037780A2 (fr) 2022-08-10
US20210093525A1 (en) 2021-04-01
AU2020360433A1 (en) 2022-03-10
CN114449993A (zh) 2022-05-06
AU2024202997A1 (en) 2024-05-23
CA3155925A1 (fr) 2021-04-08
WO2021067996A3 (fr) 2021-05-14
CA3155478A1 (fr) 2021-04-08
BR112022005059A2 (pt) 2022-06-21
EP4037779A1 (fr) 2022-08-10
CA3156259A1 (fr) 2021-04-08
MX2022003757A (es) 2022-04-18
BR112022005064A2 (pt) 2022-06-21
US20210093551A1 (en) 2021-04-01
US20230293401A1 (en) 2023-09-21
JP2022550055A (ja) 2022-11-30
US11696881B2 (en) 2023-07-11
JP7377963B2 (ja) 2023-11-10
MX2022003755A (es) 2022-05-03
WO2021067994A1 (fr) 2021-04-08
BR112022005883A2 (pt) 2022-06-21
JP7428790B2 (ja) 2024-02-06
WO2021067995A1 (fr) 2021-04-08
AU2020357202A1 (en) 2022-03-10
WO2021067992A1 (fr) 2021-04-08
US20210093549A1 (en) 2021-04-01
EP4037781A1 (fr) 2022-08-10
CN114449996A (zh) 2022-05-06
WO2021067996A2 (fr) 2021-04-08
AU2020360256B2 (en) 2024-03-28
CN114449991A (zh) 2022-05-06

Similar Documents

Publication Publication Date Title
US20210093528A1 (en) Oral Care Compositions With Anticaries Activity
AU2020359102B2 (en) Oral care compositions comprising hops beta acid and fluoride
US20220313595A1 (en) Oral Care Compositions Comprising Hops

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE PROCTER & GAMBLE COMPANY, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ST. JOHN, SAMUEL JAMES;BAIG, ARIF ALI;BIESBROCK, AARON REED;SIGNING DATES FROM 20200804 TO 20200811;REEL/FRAME:053926/0869

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS